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*CHAPTERS 1 & 3 CONTAIN MATERIAL FROM PUBLISHED WORK IN WHICH I 
WAS THE FIRST AUTHOR. THE CO-AUTHORS OF THESE PUBLICATIONS AGREE 
TO THE USE OF THE PUBLISHED DATA IN THIS DISSERTATION. 
 
CHAPTER 1 
INTRODUCTION 
1.1 Parkinson’s Disease 
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder that 
arises primarily through the loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNc), resulting in a diminished level of the neurotransmitter dopamine (DA) 
in the nigrostriatal pathway and ensuing loss of motor function {Braak, 2003}. Common 
symptoms of PD include resting tremor, muscular rigidity, bradykinesia (slowness and 
decreased amplitude of movement), along with postural instability and cognitive 
psychiatric complications {Paulus, 1991; Sherer, 2001}. PD affects 1% of the population 
≥ 65 and is the second most prevalent neurodegenerative disorder next to Alzheimer’s 
disease. {Hoehn, 1998; Recchia, 2004}. The neuropathological hallmarks of PD are 
intracellular inclusions termed, Lewy bodies (LB) and Lewy neurites (LN), composed 
primarily of insoluble aggregates of ubiquitin and α–synuclein {Gomez-Tortosa, 1999; 
Spillantini, 1998a; Spillantini, 1998b}.      
It is estimated that seven to ten million people worldwide are currently living with 
PD. The financial burden of treating PD is significant and especially troublesome for 
elderly, low-income patients. Medication expenses average approximately $2,500 per 
patient annually and the cost of therapeutic surgery can reach as much as $100,000. 
Additionally, when considering direct and indirect expenditures for PD treatment, 
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including payment of social security benefits and lost income from the inability to work, 
the cost soars to nearly $25 billion annually. 
 
1.2      Pathogenesis of PD 
In PD, the progressive loss of dopaminergic neurons, mainly in the SNc and 
ventral tegmental area, results in a depletion of DA in the basal ganglia and striatum. 
Low DA levels cause dysregulation of the motor circuits that project through this brain 
region, leading to the clinical manifestations of the disease. Although the etiology of PD 
is not yet clear and may be multifactorial, oxidative stress and mitochondrial dysfunction 
are thought to play a central role in the pathology of the disease {Cavalli, 2008}. A 
reduction in natural antioxidant defenses (glutathione, catalase, superoxide dismutase) 
has also been correlated with disease progression and susceptibility. In addition, 
increased iron concentration and protein aggregation, namely that of α–synuclein, are 
thought to be intimately associated with disease pathogenesis. These hypotheses have 
been strengthened by post-mortem studies of the PD brain, in which evidence of 
mitochondrial dysfunction, oxidative damage and elevated iron concentration and α–
synuclein aggregation have been observed (Figure 1) {Jenner, 2003b; Mandel, 2003}. 
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Figure 1. Multiple factors contributing to PD pathogenesis. 
 
1.2.1 Mitochondrial Dysfunction and Oxidative Stress 
Mitochondrial dysfunction is thought to be the leading source of increased 
oxidative and nitrosative stress observed in the brains of sporadic PD patients. 
Mounting evidence suggests a role for mitochondrial dysfunction in the pathogenesis of 
PD, specifically, defects in mitochondrial complex-I of the respiratory chain. Complex-I 
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deficits could be theorized to produce neuronal degeneration by way of decreased 
adenosine triphosphate (ATP) synthesis and damage caused by increased reactive 
oxygen species (ROS) production {Van Der Walt, 2003}. Genetic evidence that 
alterations in complex-I activity may play a role in the pathogenesis of sporadic PD is 
provided by the observation that a single nucleotide polymorphism in the gene encoding 
the nicotinamide adenine dinucleotide (NADH)-dehydrogenase 3 enzyme of complex I 
leads to a significantly lowered risk of developing PD in Caucasians {Sherer, 2002}.  
Epidemiological studies have indicated that environmental toxins and pesticides that 
inhibit complex-I activity are implicated in the pathogenesis of sporadic PD {Langston, 
1983a}. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a by-product of the 
manufacture of a synthetic opiate, inhibits complex-I activity and replicates nearly all 
features of PD in human and animal models {Dauer, 2003; Forno, 1988}. MPTP is 
converted by the enzyme monoamine oxidase B (MAO-B), in astrocytes, to its 
metabolite MPP+ (1- methyl-4-phenyl pyridinium). MPP+ is taken into DA neurons via 
affinity for the dopamine transporter (DAT), where it inhibits complex-I and leads to cell 
death {Forno, 1988}. In aged, nonhuman primates, MPTP treatment has been found to 
produce intracellular proteinaceous inclusions that bear a resemblance to immature LB, 
which are filamentous in nature and comprised of α-synuclein {Manning-Bog, 2002}. 
Paraquat, a known complex-I inhibitor with structural similarity to MPP+, induces 
selective degeneration of DA neurons along with aggregation of α–synuclein in the SNc 
of mice {McCormack, 2002; Savitt, 2006}. Systemic treatment of rats with rotenone, a 
known inhibitor of mitochondrial function, has been found to effect selective nigrostriatal 
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dopaminergic degeneration with coupled inclusion of α–synuclein fibrils {Eisenhofer, 
2004}.  
Mitochondria are exposed to an oxidative environment, as oxidative 
phosphorylation is coupled to the formation of ROS. Post-mortem analyses have 
consistently implicated oxidative damage in the pathogenesis of PD and oxidative 
damage to lipids and DNA has been found in the SNc region of the PD brain. Increased 
oxidative stress in PD may be attributed to one, or a combination, of the following 
processes: mitochondrial dysfunction, enzymatic and auto-oxidative DA metabolism, 
elevated free iron levels and compromised antioxidant defense pathways {Jenner, 
2003b}. 
 
1.2.1.1 Enzymatic and Auto-Oxidative DA Metabolism 
DA is theorized to play a role in the neurodegenerative process via both 
enzymatic and auto-oxidative metabolism (Figures 2 & 3). DA is known to undergo 
nonezymatic, auto-oxidation, leading to reactive quinones and cytotoxic free radicals 
{Eisenhofer, 2000}. Additionally, DA is metabolized catalytically by MAO-B within 
astrocytes. MAO-B levels have been found to increase with age and in association with 
neurodegenerative disease in humans {Shapira, 1990}. MAO-B-catalyzed DA 
metabolism leads to production of a highly reactive catecholaldehyde metabolite, 3,4-
dihydroxyphenylacetaldehyde (DOPAL), as well as hydrogen peroxide (H2O2) 
{Mallajosyula, 2008}. Furthermore, neurotoxicity of DOPAL has been demonstrated in 
both cell culture and animal models {Eisenhofer, 2000}. Hydrogen peroxide, a common 
by-product of both auto-oxidative and enzymatic DA metabolism, has further 
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implications, as it is converted by iron in the Fenton reaction to hydroxyl radical and 
other toxic free radical species that can contribute to the degenerative process.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Auto-oxidative metabolism of DA. 
 
 
 
 
Figure 3. Enzymatic oxidation of DA by MAO-B, yielding toxic metabolites. 
 
1.2.1.2 Increased Free Iron 
Studies have shown that free iron (Fe2+/3+) concentrations are considerably 
increased in parkinsonian SNc and within DA neurons. Under basal conditions, iron is 
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stored intracellularly in a non-toxic form by the ubiquitous protein, ferritin. Ferritin 
contains 24 α-helical subunits, comprised of both heavy(H)- and light(L)-chains. A 
significant reduction in the amount ferritin L-chains has been found in parkinsonian 
SNc. Due to the role of L-chains in iron storage within the shell of the protein, their 
decrease may lead to efflux of free iron from the protein complex. It is well established 
that free iron induces oxidative stress via initiation of the Fenton reaction (Figure 4), 
resulting in amplified hydroxyl radical production among other oxidative species. 
Hydroxyl radical is highly reactive and known to damage DNA, lipids and proteins, 
leading to further production of free radicals and propagation of the neurodegenerative 
process {Friedman, 2012}. 
 
 
 
 
 
 
Figure 4. Fenton reaction. Fe2+ and Fe3+ catalyze the conversion of hydrogen peroxide      
and superoxide anion to molecular oxygen, hydroxide anion and hydroxyl 
radical. 
 
 
1.2.1.3 Compromised Antioxidant Defense Pathways 
  An impairment of the antioxidant defenses posed by the cell can lead to 
increased oxidative stress. Under normal conditions, the generation of oxidative species 
is compensated by the action of endogenous antioxidants, including: reduced 
glutathione, glutathione reductase, glutathione peroxidase, catalase and superoxide 
dismutase (SOD) (Figure 5). Superoxide dismutases are a group of enzymes that 
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catalyze the conversion of superoxide to molecular oxygen and hydrogen peroxide. 
Additionally, hydrogen peroxide is decomposed to water by reduced glutathione, with 
the help of glutathione peroxidase at low concentration and by catalase at high 
concentrations. In PD, low levels of both glutathione and catalase have been found in 
the SNc region of the brain. Particularly, as glutathione is the major endogenous 
antioxidant produced by the cell (up to 5 mM), its significant reduction in the effected 
PD brain region leaves the DA neuron incapable of neutralizing oxidative species that 
are produced and oxidative stress remains unchecked {Fahn, 1992}. 
 
  
 
 
 
 
 
 
Figure 5. Decomposition of oxidative species via endogenous antioxidant defenses. 
 
1.2.2 α-Synuclein Aggregation 
A critical biomolecular event in PD pathogenesis is the aggregation of α–
synuclein. Alpha-synuclein is a pre-synaptic, natively unfolded, neuronal protein that 
has been located to the cytoplasm and associated with cellular phospholipid 
membranes. However, the structure and function of α–synuclein in the cell remains 
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heavily debated. Aggregation of α-synuclein has been found to occur in a nucleation-
dependent manner, in which elongation to the fibrillar form of the protein is preceded by 
smaller, oligomeric aggregates (Figure 6) {Wood, 1999}. Recent studies have 
demonstrated the oligomeric form of α–synuclein to be chiefly responsible for its 
neurotoxicity {Winner, 2011}. The mid-region of α–synuclein contains a hydrophobic, 
non-Aβ component (NAC) of Alzheimer’s disease amyloid domain, which is thought to 
enable the protein to undergo conformational change from random coil to the β-sheet 
structure found in fibrillar forms of the protein {Serpell, 2000}. The findings that fibrillar 
α-synuclein is the major constituent of LB and the A30P and A53T mutated forms of the 
protein, which are associated with autosomal dominant forms of PD, have increased 
rates of self-aggregation compared to wild-type, has led to speculation that α-synuclein 
aggregation has a prominent role in PD {El-Agnaf, 1998}. Studies have demonstrated 
aggregation of α-synuclein in the presence of oxidative stress-inducing compounds and 
metals including: Al3+, Fe3+, Cu2+, Co3+, MPTP, DA, pesticides and lipids {Uversky, 
2001a; Kowall, 2000; Cappai, 2005; Uversky, 2001b; Jo, 2000}.  
However, α-synuclein is non-toxic in nondopaminergic human cortical neurons, 
suggesting its toxicity is DA-dependent. It is hypothesized that oxidative species 
produced via DA metabolism, such as hydrogen peroxide, superoxide and dopamine 
quinones, may be involved along with iron in the oxidation and aggregation of α-
synuclein {Andersen, 2004}. Oligomeric α-synuclein is hypothesized to bind and 
permeabilize synaptic vesicles, releasing DA and leaving the protein more susceptible 
to oxidation {Volles, 2002; Lotharius, 2002}. Additionally, studies have uncovered a role 
for α-synuclein in regulation of DA biosynthesis via modulation of tyrosine hydroxylase 
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activity {Perez, 2002}. Interestingly, in embryonic midbrain cultures, α-synuclein-induced 
cell death is attenuated by depleting intracellular DA or antioxidant treatment. The 
attenuation of cell death in the absence of DA or in the presence of antioxidants 
indicates that loss of cell viability caused by α-synuclein is due to DA-dependent, 
oxidative events {Xu, 2002}. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Multiple factors influencing α-synuclein aggregation and contributing to the 
neurodegenerative process. 
 
 
 
 
1.3    Therapuetic Strategies for PD Treatment 
1.3.1 Symptomatic Treatment 
A range of therapeutic approaches have been used to treat the symptoms 
associated with PD. Since its discovery approximately 40 years ago, L-3,4-
dihydroxyphenylalanine (L-dopa) has been the “gold standard” in PD treatment. L-dopa 
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is the biosynthetic precursor to endogenous DA and most often is given in combination 
with the aromatic-L-amino acid decarboxylase inhibitor, carbidopa, which prevents 
peripheral metabolism and increases L-dopa bioavailability {Birkmayer, 2001}.  
Although L-dopa is the most effective treatment option available for reducing motor 
symptoms, chronic use and disease progression cause motor complications, such as 
dykinesia and “on-off” episodes {Tuite, 2003}. Disease progression causes an 
increased loss of dopaminergic nerve terminals and L-dopa can no longer be stored, 
resulting in motor fluctuations dependent upon circulating plasma levels of the drug 
{Mϋnchau, 2000}. Additionally, due to the metabolism of L-dopa to DA and subsequent 
oxidative stress-inducing metabolites, it has been speculated that chronic L-dopa use 
may be toxic to DA neurons and exacerbate the neurodegenerative process. Although 
the toxic effect of L-dopa has not been fully substantiated in vivo, nevertheless, 
additional medications have been utilized in order to: sustain a therapeutic benefit of L-
dopa, alleviate L-dopa-induced motor fluctuations and delay the onset of L-dopa 
treatment {Lipski, 2011; Tuite, 2003; Mϋnchau, 2000}. Common alternative/adjuvant PD 
therapies include DA agonists, selective MAO-B inhibitors and catechol-O-
methyltransferase (COMT) inhibitors (Table 1).   
  The selective and irreversible MAO-B inhibitors, selegiline (deprenyl) and 
rasagiline, prevent oxidative DA metabolism, thereby increasing synaptic DA levels and 
providing symptomatic benefit. Selegiline monotherapy in early PD delays the need for 
additional treatment by approximately one year {Parkinson Study Group, 1989}. In 
addition, selegiline can potentially reduce the necessary L-dopa dose by 30% and 
reduce symptomatic fluctuations observed with L-dopa therapy {Mϋnchau, 2000}. 
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Although selegiline has been shown to reduce PD symptoms, potential side effects, 
including enhanced L-dopa-induced dykinesia (LID) and psychiatric problems have 
been reported {Churchyard, 1997}. In Phase III clinical trials of advanced PD with motor 
fluctuations, rasagiline/L-dopa combination therapy significantly reduced the amount of 
“off” time {Nayak, 2008}. A recent study that examined the effect of rasagiline as 
monotherapy concluded that it may delay the progression of PD, an effect that cannot 
be explained by anti-symptomatic effects alone and may represent an early disease-
modifying effect {Schapira, 2006}. 
 COMT inhibitors, entacapone and tolcapone, delay the metabolism and 
elimination of L-dopa by inhibiting the enzyme, catechol-O-methyltransferase, leading to 
increased L-dopa bioavailability and stable plasma levels. Entacapone/L-dopa 
combination therapy extends the half-life of L-dopa elimination by 85% and increases 
plasma levels by 50% {Schrag, 2005; Nutt, 1994}. Furthermore, evidence suggests that 
in addition to the degree of striatal denervation, pulsatile and intermittent stimulation of 
DA receptors contributes significantly to motor fluctuations observed during L-dopa 
therapy. In MPTP-lesioned monkeys, combination L-dopa/entacapone therapy was 
found to reduce motor fluctuations compared to L-dopa treatment alone {Jenner, 
2003a; Smith, 2005}. Randomised, controlled trials have demonstrated that in PD 
patients with L-dopa-induced motor fluctuations, addition of entacapone resulted in a 
reduction of motor variability and the required L-dopa dose {Schrag, 2005}. 
DA agonists are frequently used in the management of early PD based on their 
low potential for inducing dyskinesia {Parkinson Study Group, 2000}. Pramipexole or 
ropinirole/L-dopa adjuvant therapy in PD patients with motor fluctuations can reduce 
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‘‘off’’ time by 1.0-1.5 h/day {Lieberman, 1998; Pinter, 1999}. In addition to reducing 
motor fluctuations, DA agonists partially alleviate LID, an effect most likely due to a 
30% reduction in the needed L-dopa dose {Stocchi, 2008}. Recent studies indicate that 
novel DA agonists may slow disease progression. In a clinical study of PD patients, 
pramipexole was compared to L-dopa in terms of their effect on disease progression. In 
this regard, a decreased loss of striatal DAT, a marker for PD progression, was seen in 
the case of D3 receptor-preferring pramipexole {Parkinson Study Group, 2002}. In 
patients with advanced PD, pramipexole improves motor function during “on” and “off” 
periods, reduces total “off” time and decreases the severity of “off” time {Lieberman, 
1997}. Furthermore, pramipexole and D3 receptor-preferring agonist, D-264, have 
demonstrated the ability to both improve motor dysfunction and provide a 
neuroprotective benefit in a variety of in vivo PD models {Li, 2010}. These findings 
indicate the use of D3 receptor-preferring agonists as a symptomatic and 
neuroprotective, disease-modifying treatment option for PD. 
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Table 1. Pharmacological treatments used in PD therapy. 
 
 
1.3.2   Neuroprotective Treatment 
Neuroprotective therapy aims to modify disease pathogenesis, thereby slowing 
or halting the degenerative process. Standard PD treatment options, such as L-dopa, 
are unable to slow its progression. Although no currently available drugs have been 
convincingly proven to be neuroprotective in PD, MAO-B inhibitors and DA agonists 
have demonstrated neuroprotection in both in vitro and in vivo PD models. In cellular 
models of PD, rasagiline protects against cell death induced by 6-hydroxydopamine (6-
Mechanism of Action Drugs 
DA replacement 
+ 
COMT inhibition 
 
MAO-B inhibition 
 
DA receptor agonism 
 
  
HO
HO
N
NH2
Mee
H
COOH
Caarrbiidoopaa
HN
O
N
Roopiinniirroollee
N
Mee
Mee
Seelleegiilliinnee
HO
HO
NO2
N
CN
Ennttaaccaapoonnee
O
HO
HO
NH2
O
OH
L--doopaa
HO
HO
NO2
O
Toollccaapoonnee
H
N
Raassaagiill iinnee
N
S
H2N
NH
Prraamiipeexxoollee
Brroommooccrriipttiinnee
15 
 
OHDA), MPTP and nerve growth factor deprivation {Nayak, 2008; Carvey, 2001; Li, 
2010}. The neuroprotective effect of rasagiline has been extended to the in vivo system, 
where in a rodent model of PD it was shown to protect DA neurons from the toxic 
effects of 6-OHDA. In this case, pretreatment with rasagiline prevented the loss of 
tyrosine hydroxylase (TH)-positive DA neurons in the SNc and DA terminals in the 
striatum by approximately 35% {Blandini, 2004}. 
 Pramipexole has demonstrated protection against several neurotoxins in vitro, 
including 6-OHDA, MPP+ and H2O2. In these models, the neuroprotective effect of 
pramipexole was independent of DA receptor stimulation and thought to be related to 
ROS scavenging properties {Fujita, 2006; Le, 2000; Abramova, 2002}. Recently, in both 
MPTP- and lactacystin-lesioned mouse models of PD, D-264 demonstrated significant 
neuroprotection; an effect that correlated with both D3 receptor activation and up-
regulation of brain-derived neurotrophic factor (BDNF) and glial-cell derived 
neurotrophic factor (GDNF) expression {Li, 2010}. Mechanistic studies suggest that the 
neuroprotective effect of DA agonists, specifically D3 receptor-preferring agonists, relies 
on their ability to: reduce DA turnover via activation of pre-synaptic DA autoreceptors 
and decreasing L-dopa dose, decrease ROS load through radical scavenging activity 
and activate post-synaptic DA receptors to induce expression of BDNF and GDNF 
{Carvey, 2001; Du, 2005}.  
 
1.3.2.1 Mechanisms of Neuroprotection 
The progression of PD causes an increasing number of DA neurons in the SNc 
to die. As a result, compensatory DA synthesis and metabolism in surviving neurons 
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cause increasing ROS production and a so-called “domino-effect” in DA neuron death 
{Chiueh, 1994}. MAO-B inhibitors are known to inhibit oxidative DA metabolism, thus 
reducing DA turnover and cell death {Marsden, 1990}. DA D2 and D3 receptors are 
expressed both pre- and post-synaptically. In this case, whereas post-synaptic D2 or D3 
receptor activation results in modulation of motor activity, pre-synaptic activation down-
regulates DA biosynthesis. DA agonists are hypothesized to protect DA neurons by 
reducing DA biosynthesis and metabolism via activation of pre-synaptic autoreceptors 
in conjunction with striatal-nigral feedback inhibition {Carvey, 2001; Carter, 1991}. As 
mentioned previously, DA agonist therapy reduces the needed dose of L-dopa by up to 
30%, thereby protecting DA neurons from ROS production caused by DA metabolism. 
In vivo studies demonstrate that levels of DA and related metabolites are significantly 
reduced in animals treated with DA agonists compared to L-dopa {Fahn, 2005}. Due to 
the role of ROS in the degenerative process, antioxidant properties of direct-acting DA 
agonists, such as pramipexole and ropinirole, are thought to contribute to their 
neuroprotective effect. Pramipexole is a potent ROS scavenger with spin trapping 
properties in the low micromolar range, although is neuroprotective in the low 
nanomolar range, suggesting multiple mechanisms involved in its neuroprotection 
{Carvey, 1997; Vincenzi, 1998}. 
Striatal neurotrophic activity functions as a regulatory feedback mechanism 
designed to maintain the cytoarchitectural integrity of the nigrostriatal pathway {Carvey, 
1993a; Carvey, 1993b}. Neurotrophic factors, BDNF and GDNF, have been shown to 
protect DA neurons exposed to neurotoxins 6-OHDA and MPP+ {Krobert, 1997; 
Kirschner, 1996}. The mechanism by which neurotrophic factors exert their protective 
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effect is proposed to involve alterations in pro-apoptotic signal transduction {Yang, 
1998}. Expression of the anti-apoptotic proteins, Bcl-2 and Bcl-X1, increases in 
response to oxidative stress, inhibiting cell death {Bredesen, 1995}. Treatment of 
primary mesencephalic cultures with pramipexole was found to increase the expression 
of Bcl-X1 and reduce the neurotoxicity of L-dopa {Carvey, 2001}. Evidence suggests 
that via increased Bcl-X1 expression, pramipexole is able to stabilize the mitochondrial 
transition pore {Bennett Jr., 1999}. Signal-mediated apoptosis has been shown to be 
associated with DA neuron loss in PD. Several in vitro and in vivo studies have 
indicated the ability of propargylamines, such as rasagiline, to block apoptosis {Blandini, 
2004; Yi, 2006; Olanow, 2006}. Mechanistically, rasagiline has been found to: stabilize 
mitochondrial membrane potential, reduce levels of cytochrome c and caspase-3 and 
prevent DNA fragmentation and chromatin clumping {Youdim, 2001}. 
 
1.4 DA Receptor System 
  The DA receptors are phylogenetically classified as members of the biogenic 
amine receptors and part of the “rhodopsin-like” sub-family. Further classification places 
DA receptors in the super-family of membrane-bound proteins, termed G-protein 
coupled receptors {Boeckler, 2006}. Until 1990, the DA receptor population of the brain 
and periphery was believed to consist solely of the D1 and D2 subtypes {Seeman, 
1987}. Cloning of these two receptors led to the discovery of several additional, low-
abundance DA receptors, including the D3, D4 and D5 subtypes {Bunzow, 1988; 
Monsma Jr., 1990; Zhou, 1990}. The D1-D5 subtypes are further classified on the basis 
of their inherent biochemical and pharmacological characteristics. The D1-like 
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receptors, D1 and D5, have low nanomolar affinity for DA and are stimulatory in nature, 
thereby activating the second messenger enzyme adenylyl cyclase to produce cyclic 
adenosine monophosphate (cAMP). The D2-like receptors, D2, D3 and D4, have 
nanomolar affinity for DA and are negatively coupled to adenylyl cyclase, decreasing 
cAMP production. Additionally, D2-like receptors are associated with other signal 
transduction systems, such as potassium channels and the phosphoinositide cascade 
{Levant, 1997}. The cloning of the D3 receptor in 1990, initially undertaken by Sokoloff 
and colleagues, became of particular interest due to new hypotheses that proposed the 
D3 receptor as a therapeutic target for neuropsychiatric disorders and PD {Sokoloff, 
1990}.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Generalized structure of the DA receptor. 
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1.4.1 Comparison of D2 and D3 Receptor Subtypes 
Although D2 and D3 receptors share biochemical and pharmacological 
similarities, their localizations within the CNS set them apart. Unlike D2 receptors, which 
are widely distributed among dopaminergic brain regions with highest density in the 
striatum, nucleus accumbens, olfactory tubercle and SNc, D3 receptors are found 
predominantly in limbic brain regions {Levant, 1997}. Three splice variants of the D2 
receptor have been identified to date and include D2short, D2long and D2longer {Seeman, 
2000}. These splice variants give rise to differences in size of intracellular loop 3 (IL 3), 
which is involved in G-protein-coupling and impacts signal transduction. Several 
truncated forms of D3 receptor have been reported including D3nf, which contains a 
deletion in the C-terminal region of IL3 and is nonfunctional. Studies suggest that some 
DA agonists, including DA and quinpirole, possess higher affinity for D3 receptor, 
whereas antagonists, such as haloperidol, spiperone and domperidone display higher 
affinity for D2 receptor {Sokoloff, 1990}. Although several studies have suggested a 
lack of functional coupling of D3 receptor to G-proteins, this is thought to result from D3 
receptors maintained in a low-affinity state under basal conditions and may have 
implication to the PD condition {Levant, 1997}.  
The development of selective pharmacological tools to probe the 
pathophysiological significance of the D3 receptor in PD has been uniquely challenging 
due to the sequence similarity between D2 and D3 receptors. Sequence alignment 
studies reveal a 50% sequence identity between D2 and D3 receptors, along with 63% 
sequence similarity. Moreover, when comparing the agonist binding sites of D2 and D3 
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receptors, a sequence identity of 79% and sequence similarity of 90% are reported. 
{Boeckler, 2005}. 
 
1.4.2 Potential of D3 Receptor as Therapeutic Target in PD 
The D3 receptor has gained attention as a potential therapeutic target in the 
treatment of PD. The following characteristics of D3 receptor suggest its potential role in 
PD treatment: unique CNS distribution, high affinity of DA agonists for D3 receptor, 
neuroprotective effect of D3 receptor stimulation and its role in both the development 
and modulation of LID. 
The D3 receptor has a unique distribution in the limbic and nigrostriatal brain 
regions, making it a promising target to treat neurological diseases, including PD. The 
D3 receptor contributes to the control of movement, emotion and cognition, each of 
which becomes significantly altered in PD. Additionally, while playing a role in the 
control of motor activity under normal conditions, D3 receptor may have an expanded 
and more significant role in the parkinsonian brain, in which its expression and 
distribution patterns have been found to be markedly altered {Joyce, 2001a}.  
Although it has been assumed that D2 receptor stimulation is necessary for the 
relief of motor dysfunction in PD, DA agonists have in many cases, as high or higher 
affinity for the D3 receptor. It is thought that mesolimbic D3 receptors may play a role in 
relief of PD symptoms as the limbic striatum is known to be involved in aspects of 
movement, such as goal-directed behaviors and locomotor activity {Joyce, 2001b}. 
Interestingly, locomotor stimulation is observed in 6-OHDA-lesioned rats at doses of D3 
receptor-preferring agonists that are inhibitory in normosensitive rats, suggesting that 
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D3 receptor-preferring agonists may be a viable option for antiparkinsonian treatment of 
DA-depleted animals {Van den Buuse, 1993}.  
D3 agonists have been shown to produce their neuroprotective effects by a 
variety of mechanisms, including: direct scavenging of free radicals, upregulating 
activity of radical scavenging enzymes, stabilizing mitochondrial membrane potential 
and apoptosis inhibition {Zou, 1999; Le, 2001}. Clinical studies utilizing positron 
emission tomography (PET)-imaging of nigrostriatal terminals demonstrate that D3 
receptor-preferring agonists, pramipexole and ropinirole, reduce PD disease 
progression {Clarke, 2002}.  
In monkeys rendered parkinsonian with MPTP, D3 receptor expression has been 
found to decrease significantly (68%) in the caudate nucleus. MPTP-intoxicated 
monkeys receiving chronic doses of L-dopa for several months resulted in LID 
symptoms in five of nine cases. Interestingly, D3 receptor expression was found to be 
higher in the putamen (+154%) of MPTP-intoxicated monkeys with LID compared to 
non-dyskinetic and normal monkeys. Furthermore, D3 receptor density in the putamen 
correlated with the incidence and severity of LID. PD-like symptoms and LID were 
associated with down- and up-regulation of D3 receptor expression. D3 receptor-
selective ligands have been investigated for their potential in reducing LID. Recently, 
D3 receptor-selective, mixed agonist/antagonist, BP 897, was studied in vivo to 
evaluate its ability to reduce LID. BP 897 was administered to dyskinetic, MPTP-
intoxicated monkeys in combination with L-dopa. Interestingly, BP 897 reduced LID by 
66%, while having no effect on the motor recovery provided by L-dopa {Bézard, 2003}. 
Additionally, in the unilaterally lesioned rat, simultaneous administration of L-dopa and 
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D3 receptor-selective agonist, PG01042, caused attenuation of abnormal involuntary 
movements (AIMs) in a dose-dependent manner without deleterious motor side effects 
{Riddle, 2011}. Results such as these suggest that D3 receptor-selective ligands are 
able to normalize D3 receptor function in the caudate putamen of dyskinetic animals, 
thereby treating LID symptoms.  
 
1.5   Evolution in the Development of DA Agonists 
    Early PD therapeutics consisted largely of the ergoline class of DA agonists. The 
ergot agonists are each derived from ergoline, a chemical substructure of alkaloids 
found in fungi of the genus Claviceps. The ergoline class of DA agonists display 
preferential affinity for D2-like receptors and include bromocriptine, pergolide, lisuride 
and cabergoline. Despite the early success of ergoline DA agonists in the treatment of 
PD, side effects associated with serotonergic activity and drug-drug interactions have 
limited their use and indicate the need for novel DA agonists {Kvernmo, 2006}.  
 In the words of French biologist, François Jacob, “Evolution consists largely of 
molecular tinkering.” A great deal of effort has been directed towards the development 
of novel DA agonists {Boeckler, 2006}. DA binds promiscuously to each of the DA 
receptor subtypes, although slightly higher affinities (30-40 nM) are reported at D1 
compared to D2 receptors (80-120 nM) in their high affinity states {Ross, 1991}. 
Additionally, DA has been found to bind preferentially to D3 over D2 receptor {Levant, 
1997}. Initial efforts toward the development of novel DA agonists focused on 
determining the bioactive confirmation of DA. Rigidization of the rotatable, aminoethyl 
side chain of DA produced the 2-aminotetralins, including (S)-(-)-5-hydroxy-2-(N,N-di-n-
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propylamino)tetralin [(S)-(-)-5-OH-DPAT] and (R)-(+)-7-hydroxy-2-(N,N-di-n-
propylamino)tetralin [(R)-(+)-7-OH-DPAT] {McDermed, 1976; Damsma, 1993}. 
Furthermore, these conformationally constrained analogs correspond to the α- and β-
rotamers of DA, each lacking the p-OH group (Figure 8). Structure-activity-relationship 
(SAR) studies of the 2-aminotetralins at DA receptors concluded that only the m-OH 
group of DA was necessary for binding and agonist recognition, and thus, 5- or 7-OH 
groups were sufficient for agonist activity {Cannon, 1983; McDermed, 1976; Seiler, 
1982}. Studies have indicated moderate D3 selectivity for both (S)-5-OH- and (R)-7-OH-
DPAT (D2/D3 = 26 and 60, respectively) {Van Vliet, 1996}.  
Computer models indicate the spatial orientation of conserved amino acids 
nearly identical between D2 and D3 receptors {Livingstone, 1992}. Computational 
studies have identified several amino acid residues important for agonist binding to D3 
receptors. Conserved amino acid residues, Ser-193 and Ser-196, located in 
transmembrane domain V, likely interact with the hydroxyl groups of catechols through 
hydrogen bonding, while Asp-110 of transmembrane domain III is hypothesized to 
participate in a salt-bridge with the amine group of monoamines {Sokoloff, 1990; 
Malmberg, 1994}. Moreover, the location and spatial orientation of Ser-193 and Asp -
110 appear to allow for optimal bonding to 2-aminotetralins, such as 7-OH-DPAT, which 
may confer higher affinity of these ligands at D3 compared to D2 receptor {Malmberg, 
1994}. 
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Figure 8. Rigidization of α- and β-rotamers of DA, producing 2-aminotetralins, (S)-(-)-5-
OHDPAT and (R)-(+)-7-OHDPAT. 
 
1.5.1 D3 Receptor-Selective Agonists 
The pathophysiological significance of D3 receptor in PD underscores the 
importance of developing novel DA agonists with increased selectivity for the D3 
receptor subtype. Further rigidization of 7-OH-DPAT led to the tricyclic, D3 receptor 
agonist, (+)-PD 128907, which binds to D3 receptor with high affinity (1 nM) and 
selectivity (D2/D3 = 1000) {Akunne, 1995}. Bioisosteric mimicry of the DA catechol 
nucleus has been used in an effort to obtain DA agonists with improved bioavailability, 
along with selectivity for D3 receptor. Introduction of the catechol bioisostere, 2-
aminothiazole, led to the identification of pramipexole, a preferential D3 receptor 
agonist that displays high affinity (0.5 nM) and selectivity (D2/D3 = 193) for D3 receptor 
{Sautel, 1995; Mierau, 1995; Perachon, 1999}. Mitogenesis assays indicate the intrinsic 
activity of pramipexole to be 100% at D2 and 80% at D3 receptor {Perachon, 1999}. 
25 
 
Furthermore, bioisosteric replacement with a pyrazole ring system produces quinpirole, 
a high affinity (0.96 nM), D3 receptor-selective agonist (D2/D3 = 133) {Boeckler, 2006}. 
Quinpirole demonstrates full agonism at both D2 and D3 receptor in mitogenesis assay 
{Pilon, 1994}. The pyrimidine ring system has also been utilized as a catechol 
bioisostere with several analogs displaying high affinity and selectivity for D3 receptor 
{Avenell, 1999}. 
 
1.5.2 Hybrid Structure Approach: Design of D3 Receptor-Selective Agonists 
Towards Disease-Modifying Therapeutic Agents for PD.  
As indicated previously, the high degree of structural homology shared between 
D2 and D3 receptors is a major challenge in the development of D3 receptor-selective 
agonists. Our group has devised a hybrid structure approach to the design of D3 
receptor-selective agonists {Dutta, 2002}. In this approach, 2-aminotetralins or 
bioisosteric equivalents have been tethered to aryl piperazine fragments via a suitable 
methylene linker (Figure 9). The 2-aminotetralins (5-OH- or 7-OH-DPAT) or bioisosteric 
(2-aminothiazole, pyrazole, pyrimidine etc.) equivalents impart preferential D3 agonist 
activity to the molecule, interacting with critical amino acid residues in the D3 agonist 
binding site. The adjacent aryl piperazine fragment is designed based on known D3 
antagonists and interacts with accessory binding sites within D3 receptor, thereby 
increasing D3 subtype selectivity.  
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Figure 9. Hybrid structure approach to the design of D3 receptor-selective agonists. 
 
Initial SAR studies utilizing our hybrid structure approach led to the discovery of 
7-OH-DPAT derivative, D-74. In the case of D-74, D2 and D3 receptor affinity, as well 
as D3 receptor selectivity were found to be comparable to that of 7-OH-DPAT. After 
resolution of D-74, binding and functional evaluation identified S-(-)-D-74 as the more 
biologically-active and selective enantiomer at D3 receptor. The in vivo agonist activity 
of S-(-)-D-74 was studied using the 6-OHDA-lesioned rat model of PD, where it 
displayed contralateral rotations with long duration of action {Dutta, 2004}. The 5-OH 
derivative of S-(-)-D-74, S-(-)-D-237, was also developed and displayed higher affinity 
(Table 2) and potency for D2 and D3 receptors compared to S-(-)-D-74. Moreover, S-(-
)-D-237 demonstrated significantly higher intrinsic activity in functional assays 
compared to S-(-)-D-74 and produced prolonged rotational activity in the 6-OHDA-
lesioned rat model {Biswas, 2008a}.  
Further efforts at exploring our hybrid template have focused on replacing 2-
aminotetralins with bioisosteric equivalent moieties in order to improve D3 selectivity, in 
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vivo bioavailability and antioxidant capacity of the molecule. Extension of the aryl 
piperazine fragment of S-(-)-D-237 to produce a biphenyl structure yielded the 2-
aminothiazole derivative, S-(-)-D-264 (Figure 10). This lead compound displayed high 
D3 affinity and selectivity, as well as potent D3 receptor agonist activity in binding and 
functional assays. Additionally, S-(-)-D-264 possesses comparable affinity, although 
significantly higher selectivity for D3 receptor compared to previous lead compounds 
and 7-OH-DPAT. Moreover, in terms of functional activity, S-(-)-D-264 maintained 
higher D3 selectivity and intrinsic activity (full agonist, Emax = 102%) compared to 
previous lead compounds and 7-OH-DPAT, which each displayed weak or partial 
agonist activity at D3 receptor (Table 3). In the 6-OHDA-lesioned rat, S-(-)-D-264 
induced contralateral rotations with long duration of action, suggesting efficient CNS 
penetration and antiparkinsonian effect {Biswas, 2008b}. Numerous other analogs have 
been synthesized by us in order to explore and optimize the following features of our 
hybrid template: methylene linker length, aromatic group in the aryl piperazine 
fragment, n-alkyl group and agonist head group. Data collected thus far indicate that 
compounds derived from our hybrid template have the potential for high affinity, 
potency and selectivity at D3 receptor with full agonist activity.  
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Figure 10. Development of lead compounds utilizing our hybrid template. 
 
 
Table 2. Affinity of lead compounds for cloned D2L and D3 receptors expressed in 
HEK-293 cells measured as inhibition of [3H]spiperone binding. 
 
Compound 
Ki (nM)   D2L 
[3H]spiperone 
Ki (nM) D3 
[3H]spiperone 
D2L/D3 
7-OH-DPAT 202 ± 34 2.35 ± 0.29 86 
D-74 142 ± 23 1.56 ± 0.36 91 
(S)-(-)-D-74 241 ± 7 1.88 ± 0.42 128 
(S)-(-)-D-237 26 ± 7.5 0.82 ± 0.13 31.5 
(S)-(-)-D-264 264 ± 40 0.92 ± 0.23 253 
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Table 3. Potency of lead compounds in stimulating [35S]GTPγS binding to cloned hD2 
receptor expressed in CHO cells and cloned hD3 receptor expressed in AtT-20 cells. 
 
 CHO-D2 AtT-20-D3  
Compound 
EC50 
[35S]GTPγS 
(nM) 
Emax (%) 
EC50 
[35S]GTPγS 
(nM) 
Emax (%) D2/D3 
7-OH-DPAT 39.8 ± 19.4 61.4 ± 8.6 0.531 ± 0.042 45.3 ± 2.3 74.95 
D-74 12.2 ± 0.9 32.1 ± 2.8 0.69 ± 0.39 40.5 ± 7.5 17.6 
(S)-(-)-D-237 2.22 ± 0.27 63.4 ± 3.5 0.12 ± 0.002 78.5 ± 9.5 18.3 
(S)-(-)-D-264 19.9 ± 0.9 119 ± 6 0.085 ± 0.016 102 ± 19 248 
 
A foremost goal of our PD project is to develop compounds based on our hybrid 
template that are multifunctional, not only relieving motor symptoms, but also modifying 
progression of the disease. The design of our compounds reflect the multifactorial 
nature of PD and incorporate functionality in order to achieve a molecular entity that 
addresses many of the important factors involved in disease pathogenesis. We have 
demonstrated the ability of these compounds to act as full agonists at both D2 and D3 
receptor, along with achieving high binding and functional selectivity for D3 receptor. 
Additionally, in vivo studies in PD animal models have demonstrated that these 
compounds are able to penetrate the CNS and alleviate motor dysfunction involved with 
the disease. The neuroprotective action of D3 receptor-selective agonists is well 
documented and via neurotrophic factor induction and inherent antioxidant capacity, our 
D3 receptor-selective agonists have potential as a neuroprotective therapy for PD.  
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In this work, a series of compounds were synthesized based on our well-
established hybrid template. In order to study the consequence of varying the agonist 
head group, these molecules include those containing the 5-OH-aminotetralin head 
group, in addition to those incorporating the bioisosteric equivalent moiety, 2-
aminothiazole. In the aryl piperazine region of the template, indole functionality has 
been utilized as previous studies have demonstrated its tolerability within accessory 
binding regions of D3 receptor. In addition, indole is a well known antioxidant and along 
with 2-aminothiazole, should work synergistically to produce a potent radical scavenger. 
Within this series, the effect of linker length and the nature and position of indole 
substitution on piperazine was examined in order to delineate key factors that influence 
interaction of the molecule within accessory binding pockets of the D3 receptor. 
Synthesized compounds were evaluated for their binding affinity at both D2 and D3 
receptors and molecules of interest were studied further for functional activity at these 
receptors. Based upon affinity, selectivity and potency measures, lead compounds were 
taken for in vivo examination in PD animal models. An in vitro antioxidant assay was 
then performed in order to confirm the antioxidant capacity of lead compounds. Next, 
lead compounds were evaluated in vitro for their ability to protect dopaminergic cells 
from neurotoxic insults. Lead compounds were also assessed for their ability to alter the 
aggregation process of α-synuclein. Finally, the neuroprotective effect of the 
compounds was examined in greater detail, identifying potential mechanisms involved 
in their anti-apoptotic and protective action.  
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CHAPTER 2 
SPECIFIC AIMS AND HYPOTHESES 
Dopaminergic receptor systems have been targeted in the development of 
pharmacotherapeutic agents for a number of CNS related disorders, including 
Parkinson’s disease, schizophrenia and drug addiction. Several diseases of the CNS 
have been shown to involve an imbalance in the dopaminergic system. Compelling 
evidence has suggested the use of pharmacotherapy acting via agonism, partial 
agonism or antagonism of the DA receptors to treat such imbalances. DA receptor 
agonists have been employed more extensively in the treatment of Parkinson’s disease 
than any other type of pharmacotherapy. Although the etiology of PD is still not fully 
understood, several key pathogenic factors have been identified and such discoveries 
have indicated the need for multifunctional therapy in order to treat both symptoms and 
disease progression. Our short term goals are each directed toward the development of 
multifunctional, DA D2/D3 receptor agonists with the capability of acting both as 
symptomatic and disease-modifying therapeutic agents for PD. 
     
2.1  Specific Aims 
1. Design and synthesis of DA D2/D3 receptor agonists with preferential affinity 
for D3 receptor and pharmacological characterization of these compounds 
using in vitro binding and functional assays.  
2. Perform SAR analysis to determine preference of D3 receptor for the 
geometry and substitution pattern of indole, along with optimal methylene 
linker length that results in most favorable interaction of the aryl piperazine 
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fragment within accessory binding sites of D3 receptor.  
3. Evaluate multifunctional properties of lead compounds using in vitro 
antioxidant, neuroprotection and anti-aggregation assays. Elucidate possible 
mechanisms involved in neuroprotection.   
4. Assess in vivo efficacy of lead compounds to relieve motor dysfunction in PD 
animal models.  
 
2.1.1 Hypotheses 
1. The combination of 2-aminothiazole and indole within our hybrid template 
should produce DA agonists with preferential D3 affinity and potency, as well 
as provide synergistic antioxidant capacity that will aid in the neuroprotective 
ability of our compounds. 
2. Our design of DA D2/D3 receptor agonists with preferential binding and 
functional potency for D3 receptor has the potential to both treat PD 
symptoms and modify disease progression.   
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CHAPTER 3 
RESULTS AND DISCUSSION 
3.1       Overview  
The primary goal of this work is to develop DA D2/D3 agonists with 
multifunctional properties in order to modify the symptoms and progression of PD. In 
our efforts toward this goal, we designed and synthesized a series of molecules 
containing indole within the aryl piperazine fragment, while the agonist head group was 
varied between 5-OH-aminotetralin and 2-aminothiazole. The length of the methylene 
linker, along with the geometry and substitution pattern of indole within the aryl 
piperazine fragment were varied in order to further explore accessory binding sites 
within D3 receptor. A benzamide moiety was utilized in the aryl piperazine region of our 
hybrid template in order to increase D3 receptor selectivity, as D3 antagonists are 
known to contain such functionality. These compounds were then evaluated in vitro to 
determine their D2 and D3 receptor binding affinity and selectivity. Based upon binding 
results, selected compounds were evaluated for functional properties to determine their 
potency in stimulating D2 and D3 receptors. Next, lead compounds were subjected to in 
vitro antioxidant, neuroprotection and anti-aggregation assays in order to study their 
multifunctional properties. Finally, the efficacy of lead compounds in reducing motor 
dysfunction was evaluated using PD animal models. This chapter will describe the 
following: 
1. Synthesis of all compounds and in vitro binding and functional assays.  
2. Evaluation of multifunctional properties of lead compounds using in vitro 
antioxidant, neuroprotection and anti-aggregation assays. 
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3. Assessment of in vivo efficacy of lead compounds in PD animal models. 
 
All experimental detail, including synthesis procedures and spectroscopy data, 
binding and functional assay procedures and protocols pertaining to antioxidant, 
neuroprotection, anti-aggregation and in vivo studies will be described in the Materials 
and Methods section. 
 
3.2    Chemistry 
3.2.1 Synthesis of 6-((2-(4-((1H-indolyl)methyl)piperazin-1-yl)ethyl)(propyl)amino)-  
5,6,7,8-tetrahydronaphthalen-1-ols 
 
Scheme 1 outlines the synthesis of 9a, 9b and 9c. 5-methoxy-2-tetralone 1 was 
first condensed with n-propyl amine under reductive amination conditions to yield 
secondary amine 2. In preparation of intermediate 7, Boc-piperazine 4 was N-alkylated 
using 2-bromoethanol to yield 5. Under Swern oxidation conditions, alcohol 5 was 
converted to its aldehyde derivative 6. Aldehyde 6 was subsequently condensed with 
amine 2 under reductive amination conditions to yield 7. Treatment of intermediate 7 
with aq. HBr (48%) gave amine 8. Finally, condensation of secondary amine 8 with 
properly substituted indole-carbaldehydes afforded final compounds 9a-c.  
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Scheme 1. Synthesis of 6-((2-(4-((1H-indolyl)methyl)piperazin-1-yl)ethyl)(propyl)amino) 
5,6,7,8-tetrahydronaphthalen-1-ols  
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Scheme 2. Synthesis of 6-((2-(4-(4-chloro-1H-indole)piperazin-1-yl)ethyl)(propyl)amino)-    
5,6,7,8-tetrahydronaphthalen-1-ol and corresponding 2-aminothiazole derivative  
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3.2.2 Synthesis of 6-((2-(4-(4-chloro-1H-indole)piperazin1-yl)ethyl)(propyl)amino)-  
5,6,7,8-tetrahydronaphthalen-1-ol and corresponding 2-aminothiazole derivative  
 
Scheme 2 describes the synthesis of final compounds (±)-19, (+)-19, (-)-19 and 
21. Initially, bromo-indole 10 was N-protected using triisopropylsilyl chloride in the 
presence of NaH to give intermediate 11. Palladium-catalyzed cross-coupling of 11 with 
amine 4 using PdCl2[P(o-tol)3]2 and NaOtBu in xylenes yielded 12. Successive 
deprotection of 12 in trifluoroacetic acid gave amine 13, which on selective, N-alkylation 
with (2-bromo-ethoxy)-tert-butyl-dimethyl-silane yielded compound 14. The indole 
moeity of 14 was then N-protected to give compound 15, which on selective TBDMS 
deprotection yielded alcohol 16. Intermediate 16 was converted to its aldehyde 
derivative 17, under Swern oxidation conditions. Aldehyde 17 was subsequently 
condensed with either (±), (-) or (+)-pramipexole to yield intermediates (±)-18, (-)-18 and 
(+)-18, which were each treated with trifluoroacetic acid to afford final compounds (±)-
19, (-)-19 and (+)-19. Aldehyde 17 was further condensed with 5-methoxy-1,2,3,4-
tetrahydro-naphthalen-2-yl)-propyl-amine under reductive amination conditions and 
subsequently treated with aq. HBr (48%) to furnish 21. 
 
3.2.3 Synthesis of (4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6- yl)(propyl)      
amino)ethyl) piperazin-1-yl)(1H-indol-2-yl)methanones 
 
Scheme 3 depicts the synthesis of (±)-40, (+)-40, (-)-40, (±)-41 and (±)-42. 
Indole-2-carboxylic acid was first coupled to amine 4 using EDCI as coupling reagent. 
Deprotection of piperazine, followed by selective, N-alkylation with appropriately 
substituted TBDMS-protected alkyl halides afforded intermediates 25-27. Protection of  
38 
 
Scheme 3. Synthesis of (4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6- yl)(propyl) 
amino)ethyl) piperazin-1-yl)(1H-indol-2-yl)methanones   
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the indole nitrogen, followed by selective deprotection of the hydroxyl group using n-
Bu4NF gave alcohols 31-33. Alcohols 31-33 were subsequently converted to their 
aldehyde derivative using Swern oxidation conditions to yield aldehydes 34-36. 
 
 
 
Scheme 4. Synthesis of (4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-
yl)(propyl)amino)ethyl)piperazin-1-yl)(1H-indolyl)methyl and methanone analogs   
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Aldehyde 34 was coupled with (±), (+) and (-)-pramipexole under reductive amination 
conditions to give condensed products (±)-37, (+)-37 and (-)-37. Finally, deprotection of 
the indole nitrogen afforded final compounds (±)-40, (+)-40 and (-)-40. Aldehydes 35 
and 36 were similarly condensed under reductive amination conditions with (±)-
pramipexole to yield intermediates (±)-38 and (±)-39, which were deprotected under 
acidic conditions to afford (±)-41 and (±)-42. 
 
3.2.4 Synthesis of (4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-
yl)(propyl)amino)ethyl)piperazin-1-yl)(1H-indolyl)methyl and methanone analogs 
   
Scheme 4 outlines the synthesis of (±)-45, (+)-45, (-)-45, (±)-46, (+)-46, (-)-46, 48 
and 49. Aldehyde 6 was condensed with (±), (+) or (-)-pramipexole to yield products (±)-
43, (+)-43 and (-)-43, which were subsequently treated with acid to yield intermediates 
(±)-44, (+)-44 and (-)-44. Separately and under amide coupling conditions, (±)-44, (+)-
44 and (-)-44 were each reacted with either indole-3- or indole-5-carboxylic acid to yield 
(±)-45, (+)-45, (-)-45, (±)-46, (+)-46, (-)-46. Reaction of (±)-44 with either 5-methoxy-1H-
indole-3-carboxylic acid under amide coupling conditions, or 1H-indole-5-carbaldehyde 
under reductive amination conditions, afforded intermediate 47 and 49. Finally, 
demethylation of 47 with boron tribromide furnished 48. 
 
3.2.5 Synthesis of di-acetyl and mono-(R)-lipoic acid prodrugs of (-)-45 
 Scheme 5 illustrates the synthesis of prodrugs (-)-50 and (-)-51. Acetylation of 
primary and secondary amine groups of (-)-45 was accomplished with acetic anhydride 
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and catalytic DMAP, affording (-)-50. Additionally, amide coupling of (-)-45 to (R)-lipoic 
acid, using DCC as coupling reagent, yielded (-)-51. 
 
Scheme 5. Synthesis of N-acetyl and -(R)-lipoic acid prodrugs of (-)-45 
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well tolerated, producing molecules with high D2/D3 affinity and preference for D3 
receptor {Brown, 2009}. We have carried out our binding studies with rat D2 and D3 
(rD2 and rD3) receptors expressed in HEK-293 cells and functional characterization 
with human D2 and D3 receptors (hD2 and hD3) expressed in CHO cells. In our own 
findings, we did not observe any significant difference in interaction with receptors when 
comparing rat and human D2 and D3 receptors. A high degree of homology exists 
between the two species, with 95% for D2 and 78% for D3, due to a somewhat shorter 
IL3 in the human version of the D3 receptor {Giros, 1990; Grandy, 1989}. 
Table 3 summarizes the binding data for analogues that were synthesized. 
Compounds 9a−c, which incorporate the 5-hydroxyaminotetralin head group and a 
methylene unit connecting piperazine to indole at various positions, displayed high 
affinity for D3 and moderate affinity for D2 receptors. Among this series of analogues, 
the 5-substituted indole derivative, 9a, displayed the highest selectivity (Ki, D2 = 269 
nM, D3 = 4.17 nM, D2/D3 = 64.5), while 9c (Ki, D2 = 82.1 nM, D3 = 3.20 nM, D2/D3 = 
25.6) proved to be the most potent and least selective for D3 receptor. Analogues 9a−c 
exhibited lower affinity for D2 and in the case of 9a, higher selectivity for D3 compared 
to parent compound D-237 (9a Ki, D2 = 269 nM, D2/D3 = 64.5 vs D-237 Ki, D2 = 26.0 
nM, D2/D3 = 31.5). A similar 5-substituted indole derivative, 21, displayed low selectivity 
and lost some potency (Ki, D2 = 76.4 nM, D3 = 10.4 nM, D2/D3 = 7.3) for D3 receptor 
compared to counterparts 9a−c. Compound 49, analogous to 9a−c, with 2-
aminothiazole substitution in the agonist head group, maintained D2 receptor affinity 
within the range displayed by 9a−c, while D3 affinity decreased by approximately 2-fold 
(Ki, D2 = 132 nM, D3 = 8.07 nM, D2/D3 = 16.4). 
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Previous and current results consistently demonstrate that in the 2-aminothiazole 
series of hybrid compounds, the (−)-isomeric version exhibits the highest affinity and 
selectivity for D3 receptor. Bioisosteric equivalent molecules were synthesized with the 
aminotetralin headgroup replaced with 2-aminothiazole. The first of these analogues 
incorporated a bond that linked piperazine directly to the indole moeity. The most active 
optical isomer of this molecule, (−)-19, displayed the highest affinity for D2 receptor 
among compounds in our study, along with low D3 selectivity (Ki, D2 = 39 nM, D3 = 
2.19 nM, D2/D3 = 17.8). Parent compound, D-301, displayed lower D2 affinity and 
higher D3 selectivity (Ki, D2 = 269 nM, D3 = 2.23 nM, D2/D3 = 121) compared to (-)-19. 
This suggests that the indole moiety alone does not give rise to selectivity for either 
receptor subtype. Next, in an attempt to increase D3 subtype selectivity, we 
incorporated a benzamide moiety into the aryl piperazine fragment. The benzamide 
moiety is found in a number D3 receptor-selective ligands {Boeckler, 2006}. Therefore, 
we synthesized analogues that incorporate an amide bond between the piperazine 
nitrogen atom and various positions of indole. In these molecules, D3 receptor affinity 
was maintained in the low nanomolar range, while D2 affinity dropped significantly to 
the low micromolar range. The 2-aminothiazole derived, 3-indoleacyl, (−)-45, displayed 
the highest D3 receptor selectivity (Ki, D2 = 902 nM, D3 = 1.09 nM, D2/D3 = 828) in our 
current series of molecules. A more than 3-fold increase in D3 receptor selectivity was 
observed for (−)-45 when compared to previous lead and parent compound D-264 
(D2/D3, 828 vs 253 for (−)-45 and D-264, respectively). Our next goal was to synthesize 
the isomeric, 2-indoleacyl derivative. The most active enantiomer, (−)-40, exhibited high 
affinity and selectivity for D3 receptor (Ki, D3 = 1.84 nM, D2/D3 = 583). The most active 
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enantiomer of the 5-indolacyl dertivative, (−)-46, produced a similar high affinity and 
selectivity profile for D3 receptor (Ki, D3 = 1.40 nM, D2/D3 = 736). Thus, affinity and 
selectivity for D3 receptor were similar in isomeric compounds (−)-40, (−)-45 and (−)-46. 
In order to determine the impact of linker length on D3 receptor binding, we 
varied the length of the two-carbon tether between the agonist head group and the aryl 
piperazine fragment. Compound (±)-41 (Ki, D2 = 928 nM, D3 = 2.78 nM, D2/D3 = 
333.8) contained a three-carbon linker and displayed an almost 2-fold increase in D3 
selectivity compared to parent compound (±)-40 (Ki, D2 = 852 nM, D3 = 4.59 nM, 
D2/D3 = 186). Compound (±)-42 contains a four-carbon linker and affinity for both D2 
and D3 receptors increased (Ki, D2 = 531 nM, D3 = 1.74 nM, D2/D3 = 305) compared 
to (±)-40 and (±)-41. We also modified (±)-45 to incorporate a hydroxyl substituent at 
the 5-position of indole. Hydroxyl substitution helped us to study the electronic effect of 
an electron-releasing group on the indole nucleus and a possible contribution of 
hydrogen-bond interactions in this region of D3 receptors. This modification produced 
compound 48, which maintained micromolar D2 affinity of the parent compound, while 
D3 affinity decreased 4-fold (Ki, D2 = 1,079 nM, D3 = 16.8 nM, D2/D3 = 64.2). This 
result indicated that introduction of a 5-hydroxyl group on the indole nucleus did not 
have a significant effect on D2 affinity, while D3 affinity and selectivity was impacted 
unfavorably. Compound 49 was designed to combine a methylene unit, connecting 
piperazine to indole, with a 2-aminothiazole head group. This analog displayed 
increased affinity for D2 receptors, while D3 receptor affinity and selectivity was 
diminished compared to previous analogs with amide functionality in the aryl piperazine 
fragment (Ki, D2 = 132 nM, D3 = 8.07 nM, D2/D3 = 16.4). The binding affinity of 49 
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reflected that of similar analogs, 9a-c, which contained the 5-OH-aminotetralin head 
group in place of 2-aminothiazole, underscoring the importance of the amide 
functionality in the aryl piperazine fragment on D3 affinity and selectivity. Compounds (-
)-50 and (-)-51 were designed as prodrugs of (-)-45, in order to examine the possibility 
of increasing CNS penetration and in the case of (-)-51, providing additional 
neuroprotective benefit by incorporating the disulfide antioxidant, R-(+)-lipoic acid. 
Although these studies are yet to be performed, they would be beneficial to our 
understanding of the neuroprotective action and in vivo activity of our lead compounds.     
 
 
Table 4. Competitive binding of synthesized compounds with [3H]spiroperidol to cloned 
rat D2L and D3 receptors expressed in HEK-293 cells. 
 
Compound 
Ki (nM), D2L 
[3H]spiroperidol 
Ki (nM), D3 
[3H]spiroperidol 
D2L/D3 
(-)-5-OH-DPAT 58.8 ± 11.0 1.36 ± 0.28 43.2 
D-237 26.0 ± 7.5 0.83 ± 0.13 31.5 
D-301 269  ± 16 2.23  ± 0.60 121 
D-264 264 ± 40 0.92 ± 0.23 253 
9a 269 ± 183 4.17 ± 0.36 64.5 
9b 183 ± 26 5.48 ± 0.86 33.4 
9c 82.1 ± 7.1 3.20 ± 0.32 25.6 
(±)-19 46.7 ± 6.6 1.92 ± 0.38 24.3 
(-)-19 39 ± 5 2.19 ± 0.39 17.8 
(+)-19 134 ± 12 15.9 ± 3.6 8.46 
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21 76.4 ± 2.4 10.4 ± 1.6 7.3 
(±)-40 852 ± 209 4.59 ± 0.15 185.6 
(-)-40 1,073 ± 92 1.84 ± 0.51 583 
(+)-40 2,558 ± 112 54.1 ± 4.2 47.3 
(±)-41 928 ± 152 2.78 ± 0.25 334 
(±)-42 531 ± 119 1.74 ± 0.25 305 
(±)-45 1,503 ± 67 4.17 ± 0.30 360 
(-)-45 902 ± 130 1.09 ± 0.14 828 
(+)-45 1,316 ± 244 48.2 ± 8.6 27.3 
(±)-46 1,243 ± 130 4.10 ± 0.57 303 
(-)-46 1,031 ± 182 1.40 ± 0.29 736 
(+)-46 2,626 ± 229 52.8 ± 8.3 49.7 
48 1,079 ± 139 16.8 ± 0.6 64.2 
49 132 ± 22 8.07 ± 0.93 16.4 
 
 
The next goal of our study was to investigate the functional activity of selected 
compounds at D2 and D3 receptors. The most and least selective D3 ligands, based on 
binding results, were selected for functional activity evaluation. Optically active lead 
compounds (−)-19, (−)-40, (−)-45, and (−)-46 were tested in the [35S]GTPγS functional 
assay to characterize their ability to stimulate D2 and D3 receptors in comparison to the 
endogenous ligand DA and parent compounds D-264 and D-301. Compounds (−)-40, 
(−)-45, and (−)-46 each displayed higher functional potency and selectivity for D3 
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receptor in comparison to D-264 and DA (Table 5). In particular, (−)-40 maintained high 
functional selectivity for D3 receptor (EC50, D2 = 114 nM, D3 = 0.26 nM, D2/D3 = 438), 
correlating well with binding data and exhibited full agonist activity at both D2 and D3 
receptors (Emax close to 100%). Compound (−)-40 demonstrated a 5-fold increase in 
functional potency ((EC50, D3 = 1.51 vs 0.26 for D-264 vs (−)-40)) and an almost 20-fold 
increase in functional selectivity ((D2/D3 = 22.1 vs 438 nM for D-264 vs (−)-40)) for D3 
receptor when compared to D-264. Compounds (−)-45 (EC50, D2 = 86.4 nM, D3 = 0.87 
nM, D2/D3 = 99.3) and (−)-46 (EC50, D2 = 70.7 nM, D3 = 0.56 nM, D2/D3 = 126) each 
exhibited full agonist activity (Emax not significantly different from 100%) at D2 and D3 
receptors, while their selectivity for D3 receptor dropped considerably when compared 
to binding data. In contrast to the above-mentioned indoleacyl derivatives, compound 
(−)-19 was exceptionally potent at both D2 (EC50, D2 = 2.96 nM and D3 = 1.26 nM) and 
D3 receptor. Thus, (−)-19 was indiscriminate in its activation of D2 and D3 receptors. 
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Table 5. Stimulation of [35S]GTPγS binding to cloned human D2 and D3 receptor 
expressed in CHO cells. 
 
Compound 
     CHO-D2       CHO-D3 
 
 
EC50 (nM) 
[35S]GTPγS 
% Emax 
EC50 (nM) 
[35S]GTPγS 
% Emax D2/D3 
DA 227 ± 11 100 8.57 100  26.5 
D-301 116 ± 16 88.4 ± 3.9 0.82  ± 0.20 102 ± 2 141 
D-264 33.1 ± 6.6 104 ± 5 1.51 ± 0.22 90.0 ± 4.3  22.1 
        (-)-40 114 ± 12 101 ± 5 0.26 ± 0.07 103 ± 10 438 
        (-)-45 86.4 ± 6.2 91.6 ± 5.9 0.87 ± 0.11 100 ± 6 99.3 
        (-)-46  70.7 ± 14.9   107 ± 4  0.56 ± 0.14 98.1 ± 3.3        126 
        (-)-19    2.96 ± 0.3   107 ± 3   1.26 ± 0.2 93.1 ± 4.4        2.35 
 
 
3.4 Antioxidant, Neuroprotection and Anti-aggregation studies 
3.4.1 Evaluation of Free Radical Scavenging Activity 
In our attempt to assess the multifunctional nature of our lead compounds, we 
first measured their radical scavenging capacity. The DPPH radical scavenging assay is 
known to reveal the intrinsic radical scavenging potency of a compound and correlates 
well with protective concentrations of antioxidants against neurotoxic insults in cell-
based systems {Kraus, 2005}. Scavenging of the DPPH (1,1-diphenyl-2-picrylhydrazyl) 
radical by (±)-40, (±)-45, (±)-46, (±)-19, and ascorbic acid is shown in Figure 12. Each 
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compound inhibited DPPH radical activity dose dependently. Ascorbic acid had an IC50 
of 24.9 μM in this assay procedure, whereas the IC50 for (±)-19 was 14.5 μM. All other 
compounds tested exhibited potencies comparable to that of ascorbic acid. It is clear 
from the data that the radical scavenging capacity of (±)-19 is nearly twice that of 
ascorbic acid in quenching the DPPH radical. 
 
 
 
 
 
 
 
 
 
 
Figure 11. DPPH radical scavenging activity of (±)-19, (±)-40, (±)-45, (±)-46 and 
ascorbic acid. 
 
3.4.2  Neuroprotection Studies 
3.4.2.1 Neuroprotection against 6-OHDA- and MPP+-induced cell death in MN9D 
cells 
 
In order to further assess the multifunctional capability of our lead compounds, (-
)-19 (D-512) and (-)-40 (D-440) were evaluated for their ability to protect dopaminergic 
cells from neurotoxic insults that mimic cell death in PD. The MN9D cell line was utilized 
for these experiments and is characterized as a hybridoma, derived via the somatic 
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fusion of rostral mesencephalic neurons from embryonic C57BL/6J (E14) mice and 
N18TG2 neuroblastoma cells {Choi, 1991}. MN9D cells are known to express high 
levels of TH and have high DA content. Furthermore, while exhibiting other similarities 
with DA neurons, the MN9D cell line represents one of the most suitable models for in 
vitro study of PD. In our initial studies, we carried out experiments to study the effect of 
(-)-19 and (-)-40 on the toxicity to MN9D cells caused by 6-OHDA and MPP+. The 
neurotoxins, 6-OHDA and MPP+, are known to cause DA cell death possibly via 
different mechanisms. The toxicity of 6-OHDA is initiated by ROS production, following 
its transport into the cytosol via DAT. Oxidation of 6-OHDA is known to produce p-
quinones and free radicals such as hydrogen peroxide, superoxide and hydroxyl radical, 
each of which induce apoptosis in cells {Bové, 2005; Breese, 1970}. The metabolism of 
MPTP by MAO-B produces MPP+, a neurotoxin that selectively destroys the 
nigrostriatal dopaminergic pathway and produces parkinsonian syndrome with massive 
loss of nigral DA neurons {Jackson-Lewis, 2007; Langston, 1983b; Przedborski, 2000}. 
The toxicity of MPP+ originates with its inhibition of mitochondrial complex I, thereby 
increasing oxidative stress and ultimately causing cell death {Przedborski, 2000}. 
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Figure 12. Dose-dependent effect of pre-treatment and co-treatment with D-512, D-440 
and ropinirole on cell viability of 6-OHDA-treated MN9D cells. A: MN9D cells were 
treated with different concentrations of 6-OHDA (25 μM - 125 μM). B-D: MN9D cells 
were pre-treated with D-440, D-512 and ropinirole for 1 h followed by co-treatment with 
75 μM 6-OHDA. One way ANOVA analysis followed by Tukey's Multiple Comparison 
post hoc test were performed. (**p<0.001 compared to the 6-OHDA group. ##p<0.001 
compared to the control group). 
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Figure 13. Dose-dependent effect of pre-treatment and co-treatment with D-512, D-440 
and ropinirole on cell viability of MPP+-treated MN9D cells. A: MN9D cells were treated 
with different concentrations of MPP+ (25 μM - 125 μM). B-D: MN9D cells were pre-
treated with D-440, D-512 and ropinirole for 1 h followed by co-treatment with 100 μM 
6-OHDA. One way ANOVA analysis followed by Tukey's Multiple Comparison post hoc 
test were performed. (**p<0.001 compared to the MPP+ group. ##p<0.001 compared to 
the control group). 
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In order to demonstrate the ability of each neurotoxin to produce dose 
dependent cell death, we performed control experiments to determine the LD50 dose for 
6-OHDA and MPP+ in MN9D cells (Figure 12A & 13A). The dose response profile of 
each neurotoxin revealed LD50 values of 75 μM and 100 μM for 6-OHDA and MPP+, 
respectively. Treatment of MN9D cells with (-)-19 and (-)-40 reversed the toxicity 
induced by 75 μM 6-OHDA. In the case of 6-OHDA, at doses between 5-30 μM, both (-
)-19 and (-)-40 increased cell viability significantly. Compound (-)-19 demonstrated 
potent (5 μM) neuroprotection and fully reversed 6-OHDA-induced toxicity at 20 and 30 
μM (Figure 12C). Compound (-)-40 exhibited a similar protection profile compared to (-)-
19, although it exhibited somewhat lower potency in reversing 6-OHDA-induced toxicity 
(Figure 12B). 
The neuroprotective effect of (-)-19 and (-)-40 in reversing the toxicity of MPP+ in 
MN9D cells is demonstrated in Figure 13. Data obtained from the MTT assay indicate 
that both (-)-19 and (-)-40 are able to protect MN9D cells from MPP+-induced 
neurotoxicity in a dose dependent manner. The results depicted in Figure 13C 
demonstrate that at doses of 5-30 μM, (-)-19 conferred significant protection against 
MPP+-induced toxicity. Furthermore, at 10 and 20 μM dose, (-)-19 not only reversed the 
toxicity of MPP+, but also induced cell proliferation compared to control. Compound (-)-
40 exhibited significant neuroprotection in the dose range of 10-30 μM and, at a dose of 
30 μM, was able to fully protect MN9D cells from MPP+-induced toxicity. However, 
unlike (-)-19, (-)-40 did not produce additional cell proliferation (Figure 13B). As shown 
in the case of 6-OHDA, (-)-19 was more effective in reversing MPP+-induced toxicity 
compared to (-)-40. Next, we wanted to compare the neuroprotective effect of (-)-19 
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and (-)-40 to the clinically approved PD drug, ropinirole. Interestingly, ropinirole did not 
demonstrate any significant neuroprotection against the toxicity of either 6-OHDA or 
MPP+ (Figure 12D & 13D). The cell morphology under different treatment regimes is 
depicted in Figure 14. These results underscore the neuroprotective potential of our 
lead compounds and demonstrate the inability of ropinirole to counteract the pathways 
involved in 6-OHDA- and MPP+-induced neurotoxicity. 
 
3.4.2.2 Inhibition of 6-OHDA-Induced Caspase-Induction in MN9D cells  
A possible mechanism behind the neuroprotective effect of (-)-19 and (-)-40 may 
involve reduction of 6-OHDA- and MPP+-induced oxidative stress. In order to further 
delineate the mechanisms involved in the neuroprotective effect of our lead 
compounds, we next examined the effect of (-)-19 and (-)-40 on the induction of 
caspase-3 and caspase-7 in 6-OHDA-treated MN9D cells. The caspases are a family of 
cysteine proteases that are known to play a critical role in apoptosis. Among the 
caspases, caspase-3, -6 and -7 are thought to trigger the execution phase of apoptosis 
via cleavage of several structural and repair proteins {Slee, 2001}. Previous studies 
indicate that 6-OHDA causes increased ROS production in MN9D cells and as a result, 
cell death arises via an intrinsic apoptotic pathway that involves caspase activation. 
Morphological changes accompanying 6-OHDA-induced cell death in MN9D cells 
include cytoplasmic membrane shrinkage, preservation of intracellular organelles and 
perinuclear chromatin condensation. In contrast, MPP+-induced cell death in MN9D 
cells has been shown to not involve significant ROS generation or caspase activation 
and to be accompanied by mitochondrial swelling and irregularly scattered 
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heterochromatin, characteristic of necrosis {Choi, 1999}. In order to evaluate whether (-
)-19 promotes cell survival in 6-OHDA-treated MN9D cells via inhibition of caspase 
activity, we carried out the fluorometric caspase 3/7 assay. The results from such 
experiments demonstrate that 6-OHDA treatment triggers a significant induction of 
caspase-3 activity, while (-)-19 dose dependently inhibits 6-OHDA-induced caspase 3/7 
activation in MN9D cells (Figure 15). 
 
Figure 14. Morphological changes of MN9D cells treated with control, 75 μM 6-OHDA 
(24 h), 20 μM D-512 + 75 μM 6-OHDA (1 h pre-treatment/24 co-treatment), 100 μM 
MPP+ (24 h), 20 μM D-512 + 100 μM MPP+ (1 h pre-treatment/24 co-treatment) and 20 
μM D-512 (24 h) detected under light micrograph (Magnification: 200X). 
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Figure 15. Dose-dependent inhibition of caspase-3 activity in 6-OHDA-treated MN9D 
cells by D-512. One way ANOVA analysis followed by Tukey's Multiple Comparison 
post hoc test were performed. (##p <0.01 control compared to 6-OHDA treated alone 
group. ***p <0.01 6-OHDA alone treated group compared to 6-OHDA + D-512 groups). 
 
3.4.2.3 Restoration of TH level in 6-OHDA-treated MN9D cells 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme for DA biosynthesis and 
via immunohistochemistry, it has been widely utilized as a biomarker of dopaminergic 
neurons {Margolis, 2010}. Previous in vivo studies have established that 6-OHDA 
administration causes a parkinsonian condition that is accompanied by both reduced 
TH expression and DA content {Lotharius, 1999}. Due to the high levels of TH and DA 
in MN9D cells and owing to the importance of TH as a biomarker and in the integrity of 
dopaminergic neurons, we sought to determine the effect of (-)-19 on TH levels in 6-
OHDA-treated MN9D cells. Treatment of MN9D cells with 6-OHDA produced a 
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significant reduction in TH level. Our results illustrate the ability of (-)-19 to restore TH 
level in 6-OHDA-treated MN9D cells. Interestingly, treatment of MN9D cells with (-)-19, 
in the absence of 6-OHDA, upregulated the level of TH compared to control (Figure 16). 
The results obtained from neuroprotection studies suggest that our lead compounds 
have the potential to act as neuroprotective, disease-modifying therapeutic agents for 
PD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. TH protein level in MN9D cells determined by Western blot analysis. MN9D 
cells were pretreated with 20 μM D-512 for 1 h and co-treated with 75 μM 6-OHDA for 
24 h. MN9D cells were also treated with control vehicle, D-512 and 6-OHDA alone. For 
quantification purpose protein level was normalized with respect to GAPDH protein. 
One way ANOVA analysis followed by Tukey's Multiple Comparison post hoc test were 
performed. (**p<0.05 control compared to the 6-OHDA group. **p<0.05 6-OHDA 
compared to the D-512 + 6-OHDA group). 
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3.4.3 Anti-Aggregation Studies 
  
 As mentioned previously, α-synuclein aggregation is thought to play a prominent 
role in PD pathogenesis. The mechanisms by which aggregation and associated 
neurotoxicity occur is not yet fully understood, although several factors, including DA 
and its oxidized by-prodcuts, as well as oxidative stress-inducing metals, seem to play a 
role in the aggregation process. Owing to the significant role of α-synuclein aggregation 
in the neurodegenerative process and to further study the multifunctional capability of (-
)-19, we sought to evaluate the ability of our lead compound to modify α-synuclein 
aggregation in a cell-free system. Our initial experiment examined the ability of (±)-19 to 
modify DA-induced, α-synuclein aggregation. In these studies, we utilized silver staining 
and transmission electron microscopy (TEM) to monitor the course of aggregation 
(Figures 17 & 18). We were able to demonstrate the formation of DA-induced 
oligomers, with a time-dependent increase in proportion of higher molecular weight 
aggregates (Figure 17A). Under identical experimental conditions, (±)-19 was observed 
to drastically modify the DA-induced, α-synuclein aggregation process. In the case of 
(±)-19, we observed a rapid decrease in lower molecular weight forms of α-synuclein, 
although formation of discrete oligomeric aggregates was inhibited, in comparison to 
DA treatment alone (Figure 17C). Standard antioxidant, ascorbic acid, while slightly 
reducing the kinetics and nucleation of α-synuclein, was unable to significantly modify 
DA-induced α-synuclein aggregation (Figure 17B). 
 Transmission electon microscope images show morphological and physical 
characteristics of aggregates formed under different treatment regimes (Figure 18A-C).  
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Figure 17. Silver staining of SDS-PAGE gels for aggregation experiments ran at 1400 
rpm, 37 °C and under the following conditions: A. ASN (17.5 μM) + DA (200 μM) B. 
ASN (17.5 μm) + DA (200 μm) + ascorbic acid (400 μm) C. ASN (17.5 μm) + DA (200 
μm) + (±)-19 (400 μm).  
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Figure 18. Transmission electron microscopy images at 80000x magnification to detect 
the morphology and physical characteristics of ASN samples taken from experiments 
ran under the following conditions: A. ASN (17.5 μM) + DA (200 μM) B. ASN (17.5 μm) 
+ DA (200 μm) + ascorbic acid (400 μm) C. ASN (17.5 μm) + DA (200 μm) + (±)-19 
(400 μm).  
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In comparison to ASN + DA treatment (Figure 18A), in which small globular and larger 
aggregates can be seen, co-incubation with (±)-19 demonstrated a reduction in the size 
and number of aggregates (Figure 18C). Additionally, ascorbic acid co-treatment was 
able to modify DA-induced ASN aggregation slightly, with TEM imaging showing an 
increase in size and number of small, globular oligomers and a decrease in the number 
of large aggregates (Figure 18B).        
 
3.5 In vivo Efficacy of Lead Compounds in PD Animal Models 
3.5.1 Reversal of Reserpine-Induced Hypolocomotion in Rats 
Reserpine induces depletion of catecholamines in nerve terminals, resulting in a 
cataleptic condition in rats and is a well established animal model for PD {Carlsson, 
1957}. Reserpine irreversibly blocks the vesicular monamine transporter (VMAT) in the 
cytoplasm of presynaptic neurons, thereby inhibiting the intracellular storage of 
monamines and leaving them vulnerable to metabolism. Therefore, reserpine-induced 
DA depletion leads to reduced DA levels in the synaptic cleft, resulting in akinesia 
{Carlsson, 1975; Colpaert, 1987}. All clinically approved anti-parkinsonian drugs used to 
date, including L-dopa and DA agonists, are known to attenuate motor deficits in 
reserpine-treated rats {Menzaghi, 1997}. A significant reduction of locomotion was 
observed in the animals 18 h after the administration of reserpine (5 mg/kg, sc), 
indicating the development of akinesia. Compound (-)-19 (5 μmol/kg, sc) was 
efficacious in significantly reversing akinesia in rats, compared to reserprine treatment 
alone (Figure 19). Treatment with reference drug, ropinirole (5 μmol/kg, sc), produced 
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significant locomotor activation, reaching higher levels of locomotion, but much shorter 
duration of action compared to (-)-19. On the other hand, compounds (-)-46 and (-)-40 
(10 μmol/kg, sc) each failed to produce any appreciable reversal of akinesia in 
reserpine-treated rats. 
 
Figure 19. Effect of different drugs (administered sc) upon reserpine-induced (5.0 
mg/kg) hypolocomotion in rats. Each point represents the mean ± SEM for three to six 
rats. Horizontal activity was measured as described in Materials and Methods section. 
Representation of horizontal locomotor activity is at discrete 30 min. intervals after the 
administration of (-)-19 (5 μMol/kg), (-)-46 (10 μMol/kg), (-)-40 (10 μMol/kg), and 
Ropinirole (5 μMol/kg) compared to control rats, 18 h after reserpine treatment. 
Differences among treatments were significant by one-way ANOVA analysis (F(4.95) = 
6.69 (P < 0.0001): (**) P < 0.01 ((-)-19) or (*) P < 0.05 (Ropinirole) compared to 
reserpine control (Dunnett’s analysis after one-way ANOVA).   
 
3.4.2 Induction of Contralateral Rotation in 6-OHDA-Lesioned Rats  
In order to further determine the efficacy of (-)-19 and (-)-40 in vivo, lead 
compounds were evaluated in rats carrying a unilateral lesion in the medial forebrain 
bundle, induced by application of 6-OHDA (Figure 20). The 6-OHDA-lesioned rat model 
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is considered one of the standard preclinical models for early screening of PD drugs. In 
this model, administration of 6-OHDA causes degeneration of dopaminergic cell bodies 
and fibers in the nigrostriatal pathway and the development of supersensitivity of DA 
receptors on the lesioned side ensues {Deumens, 2002}. These unilaterally lesioned 
rats are known to produce rotations contralateral to their lesion when challenged with 
direct-acting DA agonists, such as apomorphine {Ungerstedt, 1971}. Our results show 
that D2 and D3 potent agonist, (-)-19, produces dose dependent rotations with long 
duration of action. In the case of (-)-19, the highest number of rotations (contralateral 
rotations = 4555) occurred at the highest dose of the drug (10 μMol/ kg). The D3 
receptor-selective agonist, (-)-40, also produced dose dependent rotations of long 
duration, with the highest number of rotations (contralateral rotations = 4666) occurring 
at its highest dose (10 μMol/ kg).  
Interestingly, although (-)-40 failed to reverse reserpine-induced hypolocomotion 
in DA-depleted rats, it was able to produce contralateral rotation in 6-OHDA-lesioned 
rats. An explanation for this outcome rests on two main points. First, evidence suggests 
that D3 receptor number decreases in early stages of PD and similar studies have 
shown that nonresponders to antiparkinsonian medication correlate with a lower D3 
receptor number (-48%). In contrast, PD cases that remain responsive to 
antiparkinsonian drugs correlate with elevated levels (+25%) of D3 receptor {Joyce, 
2001b}. Furthermore, a post-mortem study of PD cases revealed that D3 receptor was 
reduced by 45% in the basal ganglia, while D2 receptor was elevated in similar regions 
by 15-25% {Ryoo, 1998}. Thus, it is hypothesized that in DA-depleted animals, D3 
receptor number becomes significantly reduced and may cause lack of response to 
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antiparkinsonian medication. Second, in 6-OHDA-lesioned rats it has been shown that 
the motor stimulating effect of L-dopa and other D1 receptor agonists, such as 
apomorphine, measured as contraversive rotations, becomes enhanced upon repeated 
intermittent administration. The intensity of response to an L-dopa challenge increased 
3- to 4-fold following chronic, L-dopa administration and progressively declined upon 
withdrawal of the treatment regime. Furthermore, the time course of the change in 
rotational behavior paralleled that of D3 receptor appearance and disappearance in the 
caudate putamen {Bordet, 1997}. It is hypothesized that repeated challenging of 6-
OHDA-lesioned rats with apomorphine led to D3 receptor induction in the caudate 
putamen, and motor activation, when administered D3 receptor-selective agonist, (-)-
40. Thus, each lead compound was efficacious in producing contralateral rotation in the 
6-OHDA-lesioned rat model of PD.  
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Figure 20. Effect on turning behavior of D-512 ((-)-19), D-440 ((-)-40) and ropinirole in 
6-OHDA unilaterally lesioned rats. 
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CHAPTER 4 
SUMMARY 
  
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder that 
results from the death of DA-producing cells in the SNc region of the midbrain. 
Common symptoms include: resting tremor, muscular rigidity, bradykinesia, along with 
postural instability and cognitive psychiatric complications. In PD, the progressive loss 
of dopaminergic neurons in the SNc results in a depletion of DA in the basal ganglia 
and striatum. Low DA levels cause dysregulation of the motor circuits that project 
through this brain region, leading to the clinical manifestations of the disease. Although 
the etiology of PD is not yet clear, oxidative stress and mitochondrial dysfunction are 
thought to play a central role in the pathology of the disease. A reduction in natural 
antioxidant defenses, along with increased free iron levels have also been tied to PD 
disease progression and susceptibility.  In addition, protein aggregation, namely that of 
α-synuclein, is thought to be intimately associated with disease pathogenesis. 
DA receptor agonists have been employed more extensively in the treatment of 
Parkinson’s disease than any other type of pharmacotherapy. L-dopa, the immediate 
precursor to endogenous DA, is the current gold-standard treatment option for PD. 
Although initially beneficial in reducing motor symptoms, chronic L-dopa therapy 
inevitably leads to a number of side effects including, wearing off, “on” and “off” 
episodes, production of involuntary movements and may even exacerbate the 
progression of the disease. The replacement of L-dopa by DA agonists has the 
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potential of alleviating these undesirable side effects, while also acting as both a 
symptomatic and neuroprotective therapeutic agent.   
 Utilizing our previously developed hybrid structure template, we have designed 
novel, D3 receptor-preferring agonists. These hybrid compounds contain an agonist 
binding moiety, consisting of either 5-OH-aminotetralin or 2-aminothiazole, linked to an 
aryl piperazine fragment via methylene linkage. These compounds have demonstrated 
high affinity and potency for D3 receptor. Additionally, antioxidant moieties have been 
incorporated into these molecules in order to confer radical scavenging capacity and 
the potential to protect dopaminergic cells from neurotoxic insults. These properties are 
hypothesized to address a number of the shortcomings of existing therapeutic agents 
for PD. 
After synthesis we sought to characterize our compounds using in vitro 
radioligand binding and GTPγS functional assays. Binding results pointed to (±)-19, (±)-
40, (±)-45 and (±)-46 as lead compounds due to high affinity binding of (±)-19 to D2 and 
D3 receptors, as well as high selectivity of (±)-40, (±)-45 and (±)-46 for D3 receptor. 
Next, we synthesized and evaluated both the (+) and (-)-isomeric forms of each lead 
compound and determined the (-)-isomeric form to confer the highest biological activity. 
Going forward with the (-)-isomeric form of each compound, functional studies 
characterized each of these molecules as full agonists at both D2 and D3 receptors. 
The functional potency of (-)-19 for D2 and D3 receptors remained high and correlated 
with binding affinity, while only the D3 selectivity of (-)-40 correlated well with binding 
data. 
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Next, our lead molecules were further evaluated for the antioxidant, 
neuroprotective and anti-aggregation properties. The DPPH radical scavenging assay 
was used to reveal the intrinsic radical scavenging potency of our compounds. In this 
assay procedure, (±)-19 demonstrated an IC50 of 14.5 μM, compared to that of 24.9 μM 
in the case of ascorbic acid. It was clear from the data that the radical scavenging 
capacity of (±)-19 is nearly twice that of ascorbic acid in quenching the DPPH radical. 
In order to further assess the multifunctional capability of our lead compounds, (-
)-19 and (-)-40 were evaluated for their ability to protect dopaminergic cells from 
neurotoxic insults that mimic cell death in PD. Treatment of MN9D cells with (-)-19 and 
(-)-40 reversed the toxicity induced by 75 μM 6-OHDA. Additionally, data obtained show 
that both (-)-19 and (-)-40 are able to protect MN9D cells from MPP+-induced 
neurotoxicity in a dose dependent manner. Furthermore, at 10 and 20 μM dose, (-)-19 
not only reversed the toxicity of MPP+, but also induced cell proliferation. Interestingly, 
clinically approved PD drug, ropinirole, did not demonstrate any significant 
neuroprotection against the toxicity of either 6-OHDA or MPP+. 
In order to further delineate the mechanisms involved in the neuroprotective 
effect of our lead compounds, we next examined the effect of (-)-19 and (-)-40 on the 
induction of caspase-3 and caspase-7 in 6-OHDA-treated MN9D cells. In order to 
evaluate whether (-)-19 promotes cell survival in 6-OHDA-treated MN9D cells via 
inhibition of caspase activity, we carried out the fluorometric caspase 3/7 assay. The 
results from such experiments demonstrate that 6-OHDA treatment triggers a significant 
induction of caspase-3 activity, while (-)-19 dose dependently inhibits 6-OHDA-induced 
caspase 3/7 activation in MN9D cells. 
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Tyrosine hydroxylase (TH) is the rate-limiting enzyme for DA biosynthesis and 
via immunohistochemistry, it has been widely utilized as a biomarker of dopaminergic 
neurons. Due to high levels of TH and DA in MN9D cells and owing to the importance of 
TH as a biomarker and in the integrity of dopaminergic neurons, we sought to 
determine the effect of (-)-19 on TH levels in 6-OHDA-treated MN9D cells. Treatment of 
MN9D cells with 6-OHDA alone indicated a significant reduction in TH level. 
Furthermore, our results demonstrate the ability of (-)-19 to restore TH level in 6-OHDA-
treated cells. Interestingly, treatment of MN9D cells with (-)-19, in the absence of 6-
OHDA, upregulated the level of TH. 
Next, we sought to determine the in vivo efficacy of our lead compounds in PD 
animal models. Reserpine induces depletion of catecholamines in nerve terminals, 
resulting in a cataleptic condition in rats and is a well established animal model for PD. 
A significant reduction of locomotion was observed in the animals 18 h after the 
administration of reserpine (5 mg/kg, sc), indicating the development of akinesia. 
Compound (-)-19 (5 μM/kg, sc) was efficacious in significantly reversing akinesia in rats, 
compared to reserprine treatment alone. Treatment with the reference drug, ropinirole 
(5 μM/kg, sc), produced significant locomotor activation, but much shorter duration of 
action compared to (-)-19. 
We also evaluated the efficacy of (-)-19 and (-)-40 in rats carrying a unilateral 
lesion in the medial forebrain bundle, induced by application of 6-OHDA. In this model, 
administration of 6-OHDA causes degeneration of dopaminergic cell bodies and fibers 
in the nigrostriatal pathway and development of supersensitivity to DA receptors on the 
lesioned side ensues. These unilaterally lesioned rats are known to produce rotations 
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contralateral to their lesion when challenged with direct-acting DA agonists. Our results 
show that both (-)-19 and (-)-40 produce dose dependent rotations with long duration of 
action. Interestingly, although (-)-40 failed to reverse reserpine-induced hypolocomotion 
in DA-depleted rats, it was able to produce contralateral rotation in 6-OHDA-lesioned 
rats. An explanation for this outcome rests on two main points. First, evidence suggests 
that it in DA-depleted animals D3 receptor number is significantly reduced, which may 
cause a lack of response to antiparkinsonian medication. Second, the repeated 
challenge of 6-OHDA-lesioned rats with apomorphine may have led to D3 receptor 
induction in the caudate putamen, causing motor activation upon administration of D3 
receptor-selective agonist, (-)-40. Therefore, both lead compounds were efficacious in 
producing contralateral rotation in the 6-OHDA-lesioned rat model of PD. Taken 
together, the results obtained from in vitro binding and functional studies, as well as 
antioxidant, neuroprotection, anti-aggregation and in vivo PD animal model studies 
suggest that our lead compounds have the potential to act both as symptomatic and 
disease-modifying therapeutic agents for PD.  
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CHAPTER 5 
MATERIALS AND METHODS 
5.1   Chemistry 
5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine (2). Into a stirring 
solution of n-propylamine (14.9 mL, 181.6 mmol) and ketone 1 (12.8 g, 72.6 mmol), in 
CH2Cl2 (70 mL), was added glacial acetic acid (17.3 mL, 290.5 mmol). After stirring for 
0.5 h, NaCNBH3 (11.4 g, 181.6 mmol) was added portion wise at 0 °C, followed by 
methanol (20 mL). The mixture was allowed to reach room temperature and stirred 
overnight. The reaction mixture was quenched with a saturated NaHCO3 solution at 0 
°C and extracted with ethyl acetate (3 x 100 mL). The combined organic layer was 
washed with water, brine and dried over Na2SO4. Solvent was removed under reduced 
pressure. Crude product was purified by column chromatography (EtOAc/MeOH, 9:1) to 
give compound 2 (11.1 g, 70%).1H NMR (CDCl3, 400 MHz): δ 0.96 (t, J = 7.2 Hz, 3H), 
1.54-1.65 (m, 3H), 2.09-2.16 (m, 1H), 2.52-2.74 (m, 4H), 2.88-3.07 (m, 3H), 3.81 (s, 
3H), 6.66 (d, J = 8.0 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 7.09 (t, J = 8.4 Hz, 1H).  
4-(2-Hydroxy-ethyl)piperazine-1-carboxylic acid tert-butyl ester (5). A mixture of 
compound 4 (10.0 g, 53.7 mmol), 2-bromoethanol (10.1 g, 80.6 mmol) and K2CO3 (22.3 
g, 161.1 mmol) in CH3CN (100 mL) was refluxed for 14 h according to procedure D. 
The crude material was purified by silica gel column chromatography (EtOAc/MeOH, 
20:1) to give compound 5 (7.12 g, 58%). 1H NMR (CDCl3, 400 MHz): δ 1.40 (s, 9H), 
2.40 (t, J = 4.8 Hz, 4H), 2.50 (t, J = 5.2, 2H), 3.38 (t, J = 4.8 Hz, 4H), 3.58 (t, J = 5.2 Hz, 
2H). 
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Procedure A. 4-(2-Oxo-ethyl)piperazine-1-carboxylic acid tert-butyl ester (6). Into a 
stirring solution of oxalyl chloride (5.5 g, 43.3 mmol) in CH2Cl2 (80 mL) at -78 oC, DMSO 
(6.2 mL, 78.7 mmol) was added. The reaction mixture was stirred for 0.5 h, followed by 
addition of compound 5 (5.0 g, 21.7 mmol, solution in 20 mL of CH2Cl2). The reaction 
mixture was stirred at the same temperature for 0.5 h, followed by addition of Et3N (18.2 
mL, 179.4 mmol) and stirring was continued for 1.5 h, while allowing the reaction 
mixture to reach room temperature. The reaction mixture was quenched by addition of 
a saturated solution of NaHCO3 and extracted with CH2Cl2 (3 x 100 mL). The combined 
organic layer was dried using Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by silica gel column chromatography 
(EtOAc/MeOH, 20:1) to give compound 6 (4.96 g, ~100%).  
Procedure B. 4-{2-[(5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)propyl 
amino]ethyl}piperazine-1-carboxylic acid tert-butyl ester (7). Into a stirring solution 
of amine 2 (4.76 g, 21.7 mmol) in CH2Cl2 (50 mL), aldehyde 6 (4.96 g, 21.7 mmol) was 
added. After stirring for 1 h, NaBH(OAc)3 (8.29 g, 39.1 mmol) was added portion wise 
and the mixture was stirred for 48 h at room temperature. The reaction mixture was 
quenched with a saturated solution of NaHCO3 at 0 °C and extracted with ethyl acetate 
(3 x 100 mL). The combined organic layer was dried over Na2SO4 and the solvent was 
removed under reduced pressure. Crude product was purified by column 
chromatography (EtOAc/MeOH, 20:1) to give compound 7 (6.46 g, 69%). 1H NMR 
(CDCl3, 400 MHz): δ 0.86 (t, J = 7.6 Hz, 3H), 1.20 (s, 9H), 1.30-1.52 (m, 3H), 1.90-2.12 
(m, 1H), 2.20-3.06 (m, 13H), 3.20-3.60 (m, 6H), 3.77 (s, 3H), 6.61 (d, J = 8 Hz, 1H), 
6.67 (d, J = 8 Hz, 1H), 7.05 (t, J = 7.6 Hz, 1H). 
73 
 
6-[(2-piperazin-1-yl-ethyl)-propyl amino]-5,6,7,8-tetrahydronaphthalen-1-ol (8). A 
mixture of compound 7 (6.46 g, 14.9 mmol) and 48% aq. HBr (40 ml) was refluxed at 
125 °C for 12 h. The reaction mixture was evaporated to dryness and a saturated 
solution of NaHCO3 was added into it at 0 °C. The reaction mixture was then extracted 
with ethyl acetate (3 x 100 mL). The combined organic layer was dried over Na2SO4, 
filtered, and concentrated under reduced pressure to yield compound 8 (3.80 g, 80%). 
1H NMR (CD3OD, 400 MHz): δ 1.06 (t, J = 7.2 Hz, 3H), 1.80-2.02 (m, 3H), 2.36-2.48 (m, 
1H), 2.60- 2.80 (m, 1H), 2.96-4.02 (m, 18H), 6.61 (d, J = 8 Hz, 1H), 6.66 (d, J = 8 Hz, 
1H), 6.96 (t, J = 8 Hz, 1H).  
6-({2-[4-(1H-indol-5-ylmethyl)piperazin-1-yl]ethyl}propyl amino)-5,6,7,8-tetrahydro 
naphthalen-1-ol (9a). Amine 8 (200 mg, 0.63 mmol) was reacted with 1H-indole-5-
carbaldehyde (91 mg, 0.63 mmol) and NaBH(OAc)3 (240 mg, 1.13 mmol) in CH2Cl2 (15 
mL) using procedure B. The crude residue was purified by column chromatography 
(MeOH/EtOAc, 1:6) to afford compound 9a (220 mg, 79%). 1H NMR (CDCl3, 400 MHz): 
δ 0.86 (t, J = 7.2 Hz, 3H), 1.30-1.52 (m, 3H), 1.90-2.10 (m, 1H), 2.46-3.02 (m, 19H), 
3.76 (s, 2H), 6.51 (d, J = 8 Hz, 1H), 6.67 (d, J = 8 Hz, 1H), 6.94 (t, J = 7.6 Hz, 1H), 7.06-
7.25 (m, 3H), 7.36 (d, J = 8 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 8.26 (bs, 1H). 13C (CDCl3, 
100 MHz): δ 12.0, 22.3, 24.0, 25.7, 29.9, 32.4, 47.9, 52.8, 53.5, 53.6, 53.8, 57.4, 58.7, 
111.2, 112.2, 119.6, 121.4, 122.1, 123.6, 124.2, 126.3, 128.2, 136.5, 138.5, 154.2, 
171.4. The free base was converted to its hydrochloride salt. M.p. 165-169  oC. Anal. 
calculated for C30H46.5Cl3.5N4O: C, H, N. 
6-({2-[4-(1H-indol-2-ylmethyl)piperazin-1-yl]ethyl}propyl amino)-5,6,7,8-tetrahydro 
naphthalen-1-ol (9b). Amine 8 (200 mg, 0.63 mmol) was reacted with 1H-Indole-2-
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carbaldehyde (91 mg, 0.63 mmol) and NaBH(OAc)3 (240 mg, 1.13 mmol) in CH2Cl2 (15 
mL) using procedure B. The crude residue was purified by column chromatography 
(MeOH/EtOAc, 1:6) to afford compound 9b (225 mg, 81%). 1H NMR (CDCl3, 400 MHz): 
δ 0.90 (t, J = 7.2 Hz, 3H), 1.40-1.71 (m, 3H), 1.96-2.10 (m, 1H), 2.36-3.08 (m, 19H), 
3.77 (s, 2H), 5.36 (bs, 2H), 6.39 (s, 1H), 6.60 (dd, J = 7.2 Hz, 1H), 6.95 (t, J = 7.6 Hz, 
1H), 7.04-7.12 (m, 2H), 7.17 (t, J = 7.6 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.4 
Hz, 1H). 13C (CDCl3, 100 MHz): δ 12.1, 21.6, 24.0, 25.4, 28.4, 30.0, 31.8, 47.5, 52.5, 
52.8, 53.2, 53.6, 55.5, 57.2, 57.8, 103.0, 111.3, 119.9, 120.5 122.0, 123.7, 126.0, 
128.3, 133.8, 136.7, 137.6, 154.6, 178.0. The free base was converted to its 
hydrochloride salt. M.p. 180-185 ºC. Anal. calculated for C28H47Cl4N4O3.5: C, H, N. 
6-({2-[4-(1H-indol-3-ylmethyl)piperazin-1-yl]ethyl}propyl amino)-5,6,7,8-tetrahydro 
naphthalen-1-ol (9c). Amine 8 (200 mg, 0.63 mmol) was reacted with 1H-indole-3-
carbaldehyde (91 mg, 0.63 mmol) and NaBH(OAc)3 (240 mg, 1.13 mmol) in CH2Cl2 (15 
mL) using procedure B. The crude residue was purified by column chromatography 
(MeOH/EtOAc, 1:6) to afford compound 9c (213 mg, 77%). 1H NMR (CDCl3, 400 MHz): 
δ 0.85 (t, J = 7.2 Hz, 3H), 1.20-1.56 (m, 2H), 1.80-2.04 (m, 1H), 2.20-3.00 (m, 18H), 
3.20-3.45 (m, 2H), 3.74 (s, 2H), 6.48 (d, J = 7.6 Hz, 1H), 6.57 (d, J = 7.6 Hz, 1H), 6.93 
(t, J = 7.2 Hz, 1H), 7.02-7.25 (m, 3H), 7.35 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 7.6, 1H), 
8.24 (s, 1H). 13C (CDCl3, 100 MHz): 12.0, 22.5, 25.4, 26.0, 26.7, 29.9, 48.4, 52.9, 53.7, 
58.3, 58.6, 63.6, 102.6, 111.0, 117.5, 121.7, 124.0, 124.7, 128.1, 128.8, 135.5, 145.2, 
165.9. The free base was converted to its hydrochloride salt. M.p. 180-185  oC. Anal. 
calculated for C28H47Cl4N4O3.5: C, H, N. 
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5-Bromo-1-(triisopropylsilyl)-1H-indole (11). Into a stirring solution of NaH (4.03 g, 
170.0 mmol) in dry THF (150 mL), compound 10 (16.44 g, 83.9 mmol) was added 
portion wise at 0 °C. The reaction mixture was allowed to stir at room temperature for 1 
h, followed by dropwise addition of triisopropylsilyl chloride (20 g, 103.7 mmol). The 
reaction mixture was stirred for 12 h and then filtered through celite. The crude residue 
was purified by column chromatography using hexane as solvent to afford compound 
11 (22 g, 75%). 1H NMR (CDCl3, 400 MHz): δ 1.23 (s, 18H), 1.74 (heptet, J = 7.6 Hz, 
3H), 6.64 (d, J = 3.2 Hz, 1H), 7.07 (d, J = 6 Hz, 1H), 7.14 (s, 1H), 7.31 (d, J = 3.2 Hz, 
1H), 7.45 (d, J = 8.8, 1H). 
tert-Butyl 4-(1-(triisopropylsilyl)-1H-indol-5-yl)piperazine-1-carboxylate (12). A 
mixture of compound 11 (22.0 g, 63.0 mmol), 4 (11.71 g, 63.0 mmol), PdCl2[P(O-tol)3]2 
(2.47 g,  3.1 mmol) and NaOtBu (9.08 g, 94.4 mmol) in xylenes (175 mL) was heated at 
110 oC for 12 h. The reaction mixture was filtered through celite and concentrated in 
vacuo. The crude residue was purified by column chromatography (EtOAc/hexane, 
1:20) to afford compound 12 (13.22 g, 46%). 1H NMR (CDCl3, 400 MHz): δ 1.19 (s, 
18H), 1.55 (s, 9H), 1.74 (heptet, J = 6.8 Hz, 3H), 3.14 (bs, 4H), 3.67 (bs, 4H), 6.60 (t, J 
= 6 Hz, 1H), 6.94 (d, J = 8.8, 1H), 7.19 (s, 1H), 7.26 (t, J = 2.8 Hz, 1H), 7.47 (d, J = 8.8 
Hz, 1H). 
Procedure C. 5-Piperazin-1-yl-1H-indole (13). To a stirring solution of compound 12 
(7.70 g, 16.8 mmol) in CH2Cl2 (15 mL), TFA (15 mL) was added slowly at room 
temperature and the reaction mixture was stirred for 2 h. Unreacted TFA and solvent 
were removed under reduced pressure and the salt was washed with diethylether. A 
saturated solution of NaHCO3 was added to the salt, followed by extraction with CH2Cl2 
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(3 x 50 mL). The combined organic layer was dried over Na2SO4, filtered and 
evaporated in vacuo to provide compound 13 (2.88 g, 85%). 1H NMR (CDCl3, 400 
MHz): δ 1.85 (bs, 1H), 2.80-3.28 (m, 8H), 6.85-7.10 (m, 1H), 7.02-7.40 (m, 4H), 8.31 
(bs, 1H). 
Procedure D. 5-{4-[2-(tert-butyl-dimethyl-silanyloxy)ethyl]piperazin-1-yl}-1H-indole 
(14). A mixture of compound 13 (2.88 g, 14.3 mmol), (2-bromoethoxy)-tert-butyl-
dimethylsilane (3.42 g, 14.3 mmol) and K2CO3 (5.93 g, 42.9 mmol) in CH3CN (50 mL) 
was refluxed for 14 hours. After filtration, acetonitrile was evaporated under reduced 
pressure and the crude material was purified by silica gel column chromatography 
(EtOAc/hexane, 3:1) to give compound 14 (4.01 g, 78%).1H NMR (CDCl3, 400 MHz): δ 
0.02 (s, 6H), 0.83 (s, 9H), 2.30-2.80 (m, 6H), 2.82-3.30 (m, 4H), 3.52-3.82 (m, 2H), 
6.25-6.48 (m, 1H), 6.75-7.30 (m, 4H), 8.09 (s, 1H).  
5-{4-[2-(tert-butyl-dimethyl-silanyloxy)ethyl]piperazin-1-yl}indole-1-carboxylic acid 
tert-butyl ester (15). Amine 14 (4.0 g, 11.1 mmol) was reacted with (Boc)2O (2.68 g, 
12.2 mmol) and DMAP (1.49 g, 12.2 mmol) in THF (50 mL) at room temperature using 
procedure G. The crude material was purified by column chromatography over silica gel 
(EtOAc/hexane, 1:1) to give compound 15 (5.2 g, ~100%). 1H NMR (CDCl3, 400 MHz): 
δ 0.08 (s, 6H), 0.95 (s, 9H), 1.65 (s, 9H), 2.61 (t, J = 6.4 Hz, 2H), 2.73 (t, J = 4.8 Hz, 
4H), 3.19 (t, J = 4.8 Hz, 4H), 3.81 (t, J = 6.4 Hz, 2H), 6.47 (d, J = 3.6 Hz, 1H), 7.01 (dd, 
J = 6.4, 2.4 Hz, 1H), 7.06 (dd, J = 6.4, 2.4 Hz, 1H), 7.53 (s, 1H), 8.00 (s, 1H).  
Procedure E. 5-[4-(2-hydroxy-ethyl)piperazin-1-yl]indole-1-carboxylic acid tert-
butyl ester (16). Into a stirring solution of compound 15 (2.0 g, 4.3 mmol) in THF (30 
mL), n-tetrabutylammonium fluoride (1.14 g, 4.3 mmol, 1.0 M solution in THF) was 
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added at 0 °C. The reaction mixture was then stirred at room temperature for 1 h. THF 
was evaporated in vacuo, the residue was diluted with CH2Cl2 (50 mL) and washed with 
water. The water layer was extracted with CH2Cl2 (3 x 75 mL). The combined organic 
layer was washed with brine, dried over Na2SO4, and evaporated. The crude product 
was purified by silica gel column chromatography (EtOAc/MeOH, 20:1) to yield 
compound 16 (1.49 g, 99%). 1H NMR (CDCl3, 400 MHz): δ 1.65 (s, 9 H), 2.61 (t, J = 5.2 
Hz, 2H), 2.70 (t, J = 4.8 Hz, 4H), 3.19 (t, J = 4.8 Hz, 4H), 3.67 (t, J = 5.2 Hz, 2H), 6.47 
(d, J = 3.6 Hz, 1H), 7.01 (dd, J = 6.8, 2 Hz, 1H), 7.06 (d, J = 2 Hz, 1H), 7.53 (s, 1H), 
8.00 (s, 1H). 
5-[4-(2-Oxo-ethyl)piperazin-1-yl]indole-1-carboxylic acid tert-butyl ester (17). 
Compound 16 (1.49 g, 4.3 mmol) was reacted with oxalyl chloride (0.75 mL, 8.6 mmol), 
DMSO (1.23 mL, 17.3 mmol) and Et3N (3.6 mL, 25.8 mmol) in CH2Cl2 (40 mL) using 
procedure A. The crude residue was purified by column chromatography using ethyl 
acetate as solvent to afford compound 17 (1.23 g, 83%).  
 5-(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propyl 
amino]ethyl}piperazin-1-yl)indole-1-carboxylic acid tert-butyl ester [(±)-18]. 
Compound 17 (175 mg, 0.51 mmol) was reacted with (±)-pramipexole (108 mg, 0.51 
mmol) and NaBH(OAc)3 (194 mg, 0.92 mmol) in CH2Cl2 (15 mL) according to procedure 
B. The crude product was purified by silica gel column chromatography (EtOAc/MeOH, 
20:1) to yield compound (±)-18 (150 mg, 55%). 1H NMR (CDCl3, 400 MHz): δ 0.91 (t, J 
= 6.8 Hz, 1H), 1.35-1.60 (m, 2H), 1.67 (s, 9H), 1.89-2.10 (m, 1H), 2.30-3.30 (m, 20H), 
4.94 (bs, 2H), 6.67 (t, J = 3.2 Hz, 1H), 7.09 (dd, J = 8.8, 2.8 Hz, 1H), 7.28 (dd, J = 3.2 
Hz, 1H), 7.59 (s, 1H), 7.97 (d, J = 6.4 Hz, 1H).   
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(S)-5-(4-{2-[(2-Amino-4,5,6,7-tetrahydro benzothiazol-6-yl)propyl amino]ethyl} 
piperazin-1-yl)indole-1-carboxylic acid tert-butyl ester [(-)-18]. Compound 17 (175 
mg, 0.51 mmol) was reacted with (-)-pramipexole (108 mg, 0.51 mmol) and 
NaBH(OAc)3 (194 mg, 0.92 mmol) in CH2Cl2 (15 mL) using procedure B. The crude 
residue was purified by column chromatography (EtOAc/MeOH, 20:1) to afford 
compound (-)-18 (161 mg, 59%). 1H NMR (CDCl3, 400 MHz): δ 0.93 (t, J = 6.8 Hz, 1H), 
1.35-1.60 (m, 2H), 1.68 (s, 9H), 1.89-2.10 (m, 1H), 2.30-3.30 (m, 20H), 4.94 (bs, 2H), 
6.67 (t, J = 3.2 Hz, 1H), 7.09 (dd, J = 8.8, 2.8 Hz, 1H), 7.28 (dd, J = 3.2 Hz, 1H), 7.60 (s, 
1H), 7.97 (d, J = 6.4 Hz, 1H).   
(R)-5-(4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)propyl 
amino]ethyl}piperazin-1-yl)indole-1-carboxylic acid tert-butyl ester [(+)-18]. 
Compound 17 (175 mg, 0.51 mmol) was reacted with (+)-pramipexole (108 mg, 0.51 
mmol) and NaBH(OAc)3 (194 mg, 0.92 mmol) in CH2Cl2 (15 mL) using procedure B. 
The crude residue was purified by column chromatography using (EtOAc/MeOH, 20:1) 
to afford compound (+)-18 (164 mg, 60%). 1H NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 6.8 
Hz, 1H), 1.37-1.60 (m, 2H), 1.67 (s, 9H), 1.89-2.10 (m, 1H), 2.30-3.30 (m, 20H), 4.94 
(bs, 2H), 6.67 (t, J = 3.2 Hz, 1H), 7.10 (dd, J = 8.8, 2.8 Hz, 1H), 7.28 (dd, J = 3.2 Hz, 
1H), 7.59 (s, 1H), 7.98 (d, J = 6.4 Hz, 1H).   
N6-{2-[4-(1H-Indol-5-yl)piperazin-1-yl]ethyl}-N6-propyl-4,5,6,7-tetrahydro 
benzothiazole-2,6-diamine [(±)-19]. Compound (±)-18 (150 mg, 0.28 mmol) was 
reacted with TFA (10 mL) in CH2Cl2 (10 mL) using procedure C. Unreacted TFA and 
solvent were removed in vacuo and the salt was washed with diethylether and 
recrystallized from ethanol to afford compound (±)-19 (106 mg, 38%). 1H NMR (CD3OD, 
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400MHz): δ 0.99 (t, J = 7.2 Hz, 3H), 1.52-1.74 (m, 2H), 1.76-2.04 (m, 1H), 2.19 (d, J = 
9.2 Hz, 1H), 2.52-2.84 (m, 6H), 3.10-3.58 (m, 13H), 6.50 (d, J = 3.2 Hz, 1H), 7.05 (d, J 
= 8.8 Hz, 1H), 7.29 (d, J = 3.2 Hz, 1H), 7.34 (d, J = 8.8 Hz, 2H). 13C (CD3OD, 100 MHz): 
δ 12.0, 22.2, 24.0, 25.1, 47.0, 51.1, 54.4, 54.8, 59.2, 101.4, 101.5, 111.8, 115.3, 116.1, 
127.8, 129.7, 135.1, 136.0, 140.7, 171.0. M.p. 110-115 ºC. Anal. calculated for 
C30H40F9N6O7.5S: C, H, N. 
(S)-N6-{2-[4-(1H-Indol-5-yl)piperazin-1-yl]ethyl}-N6-propyl-4,5,6,7-tetrahydro 
benzothiazole-2,6-diamine [(-)-19]. Compound (-)-18 (150 mg, 0.28 mmol) was 
reacted with TFA (10 mL) in CH2Cl2 (10 mL) using procedure C. Unreacted TFA and 
solvent were removed in vacuo and the salt was washed with diethylether and 
recrystallized from ethanol to afford compound (-)-19 (120 mg, 43%). 1H NMR (CD3OD, 
400MHz): δ 0.98 (t, J = 7.2 Hz, 3H), 1.54-1.74 (m, 2H), 1.76-2.04 (m, 1H), 2.19 (d, J = 
9.2 Hz, 1H), 2.52-2.84 (m, 6H), 3.10-3.58 (m, 13H), 6.51 (d, J = 3.2 Hz, 1H), 7.05 (d, J 
= 8.8 Hz, 1H), 7.29 (d, J = 3.2 Hz, 1H), 7.34 (d, J = 8.8 Hz, 2H). 13C (CD3OD, 100 MHz): 
δ 12.0, 22.3, 24.0, 25.1, 47.0, 51.1, 54.5, 54.8, 59.2, 101.4, 101.6, 111.8, 115.3, 116.1, 
127.8, 129.7, 135.1, 136.0, 140.8, 171.0. [α]25D = −11.0° (c = 1.0, CH3OH). M.p. 115-
120 oC. Anal. calculated for C31H37.5F10.5N6O7S: C, H, N. 
(R)-N6-{2-[4-(1H-Indol-5-yl)-piperazin-1-yl]ethyl}-N6-propyl-4,5,6,7-tetrahydro 
benzothiazole-2,6-diamine [(+)-19]. Compound (+)-18 (150 mg, 0.28 mmol) was 
reacted with TFA (10 mL) in CH2Cl2 (10 mL) using procedure C. Unreacted TFA and 
solvent were removed in vacuo and the salt was washed with diethylether and 
recrystalized from ethanol to afford compound (+)-19 (140 mg, 50%). 1H NMR (CD3OD, 
400MHz): δ 0.98 (t, J = 7.2 Hz, 3H), 1.54-1.78 (m, 2H), 1.76-2.04 (m, 1H), 2.20 (d, J = 
80 
 
9.2 Hz, 1H), 2.52-2.84 (m, 6H), 3.10-3.58 (m, 13H), 6.51 (d, J = 3.2 Hz, 1H), 7.05 (d, J 
= 8.8 Hz, 1H), 7.29 (d, J = 3.2 Hz, 1H), 7.34 (d, J = 8.8 Hz, 2H). 13C (CD3OD, 100 MHz): 
δ 12.2, 22.3, 24.0, 25.1, 47.0, 51.2, 54.5, 54.8, 59.2, 101.4, 101.6, 111.8, 115.3, 116.1, 
127.8, 129.7, 135.1, 136.2, 140.8, 171.0. [α]25D = +15.5° (c = 1.0, CH3OH). M.p. 115-
120 °C. Anal. calculated for C31H37.9F10.5N6O7.2S: C, H, N. 
tert-Butyl 5-(4-(2-((5-methoxy-1,2,3,4-tetrahydronaphthalen-2-
yl)(propyl)amino)ethyl) piperazin-1-yl)-1H-indole-1-carboxylate (20). Aldehyde 17 
(320 mg, 0.93 mmol) was reacted with amine 2 (204 mg, 0.93 mmol) and NaBH(OAc)3 
(355 mg, 1.68 mmol) in CH2Cl2 (20 mL) using procedure B. The crude material was 
purified by column chromatography over silica gel (EtOAc/hexane, 1:1) to give 
compound 20 (190 mg, 38%). 1H NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 7.2 Hz, 3H), 
1.33-1.75 (m, 13H), 1.95-2.13 (m, 1H), 2.35-3.23 (m, 18H), 3.81 (s, 3H), 6.55-6.77 (m, 
3H), 7.03-7.15 (m, 3H), 7.58 (d, J = 2.4 Hz, 1H), 7.96 (d, J = 6.8 Hz, 1H). 
6-({2-[4-(1H-Indol-5-yl)piperazin-1-yl]-ethyl}propyl amino)-5,6,7,8-tetrahydro 
naphthalen-1-ol (21). A mixture of compound 20 (60 mg, 0.11 mmol) and 48% aq. HBr 
(10 ml) was refluxed for 5 h. The reaction mixture was evaporated to dryness and the 
residue was washed with diethylether. Finally, the HBr salt was recrystalized from 
ethanol to furnish compound 21 (50 mg, 60%). 1H NMR (CD3OD, 400 MHz): δ 0.95 (t, J 
= 7.2 Hz, 3H), 1.41-1.57 (m, 3H), 2.00-2.22 (m, 1H), 2.58-3.18 (m, 19H), 6.61 (d, J = 8 
Hz, 1H), 6.75 (d, J = 8 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 7.19-7.38 (m, 3H), 7.51 (d, J = 
8 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 8.50 (bs, 1H). M.p. 250-260 ºC. Anal. calculated for 
C27H41.4Br4N4O1.7: C, H, N. 
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Procedure F. 4-(1H-indole-2-carbonyl)piperazine-1-carboxylic acid tert-butyl ester 
(23). To a stirring solution of EDCI.HCl (15.45 g, 80.6 mmol) in CH2Cl2 (150 mL), acid 
derivative 22 (10.39 g, 64.5 mmol) was added at room temperature. The reaction 
mixture was stirred for 0.5 h, followed by addition of amine 4 (10.0 g, 53.7 mmol), HOBt 
(10.89 g, 80.6 mmol) and Et3N (22.46 g, 161.2 mmol). The reaction mixture was stirred 
for 3 h, followed by addition of a saturated solution of NaHCO3. The aqueous layer was 
extracted with CH2Cl2 (3 x 150 mL). The combined organic layer was dried over 
Na2SO4, evaporated under reduced pressure and the crude product was purified by 
flash column chromatography (CH2Cl2/MeOH, 50:1) to afford compound 23 (15.6 g, 
88%). 1H NMR (CDCl3, 400 MHz): δ 1.49 (s, 9H), 3.56 (t, J = 5.6 Hz, 4H), 3.74-4.04 (m, 
4H), 6.78 (s, 1H), 7.15 (t, J = 7.6 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.43 (d, J = 8.4 Hz, 
1H), 7.65 (d, J = 8.4 Hz, 1H), 9.14 (bs, 1H). 
(1H-Indol-2-yl)-piperazin-1-yl-methanone (24). Compound 23 (12 g, 36.4 mmol) was 
reacted with TFA (20 mL) in CH2Cl2 (20 mL) using procedure C to provide compound 
24 (7.85 g, 94%). 1H NMR (CDCl3, 400 MHz): δ 2.52-3.04 (m, 4H), 3.60-4.06 (m, 4H), 
6.77 (s, 1H), 7.14 (t, J = 7.6 Hz, 1H), 7.27 (d, J = 6.8 Hz, 1H), 7.43 (d, J = 6.8 Hz, 1H), 
7.65 (d, J = 6.8 Hz, 1H), 9.50 (bs, 1H). 
{4-[2-(tert-Butyldimethylsilanyloxy)ethyl]piperazin-1-yl}-(1H-indol-2-yl)methanone 
(25). Compound 24 (2.50 g, 10.9 mmol) was reacted with (2-bromo-ethoxy)-tert-butyl-
dimethylsilane (3.13 g, 13.1 mmol) and K2CO3 (4.52 g, 32.7 mmol) in CH3CN (50 mL) 
using procedure D. The crude material was purified by silica gel column 
chromatography using ethyl acetate as solvent to give compound 25 (3.55 g, 84%). 1H 
NMR (CDCl3, 400 MHz): δ 0.09 (s, 6H), 0.92 (s, 9H), 2.02-2.80 (m, 6H), 3.01-4.20 (m, 
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6H), 6.77 (s, 1H), 7.11 (t, J = 7.6 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 8.0 Hz, 
1H), 7.63 (d, J = 8 Hz, 1H), 10.4 (bs, 1H). 
{4-[3-(tert-Butyldimethylsilanyloxy)propyl]piperazin-1-yl}-(1H-indol-2-yl)methanone 
(26). Compound 24 (2.50 g, 10.9 mmol) was reacted with (3-bromo-propoxy)-tert-butyl-
dimethylsilane (3.31 g, 13.1 mmol) and K2CO3 (4.52 g, 32.7 mmol) in CH3CN (50 mL) 
using procedure D. The crude material was purified by silica gel column 
chromatography (EtOAc/hexane, 1:1) to give compound 26 (3.33 g, 76%). 1H NMR 
(CDCl3, 400 MHz): δ 0.06 (s, 6H), 0.90 (s, 9H), 1.52-1.86 (m, 2H), 2.45-2.70 (m, 6H), 
3.68 (t, J = 12 Hz, 2H), 3.72-4.20 (m, 4H), 6.78 (s, 1H), 7.14 (t, J = 7.6 Hz, 1H), 7.20-
7.32 (m, 2H), 7.43 (d, J = 7.6 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 9.35 (s, 1H). 
{4-[4-(tert-Butyldimethylsilanyloxy)butyl]piperazin-1-yl}-(1H-indol-2-yl)methanone 
(27). Compound 24 (2.50 g, 10.9 mmol) was reacted with (4-bromo-butoxy)-tert-butyl-
dimethylsilane (3.50 g, 13.1 mmol) and K2CO3 (4.52 g, 32.7 mmol) in CH3CN (50 mL) 
using procedure D. The crude material was purified by silica gel column 
chromatography (EtOAc/hexane, 2:3) to give compound 27 (4.31 g, 95%). 1H NMR 
(CDCl3, 400 MHz): δ 0.05 (s, 6H), 0.90 (s, 9H), 1.47-1.75 (m, 4H), 2.40 (t, J = 6.4 Hz, 
2H), 2.53 (t, J = 4.4 Hz, 4H), 3.64 (t, J = 5.6 Hz, 2H), 3.80-4.05 (m, 4H), 6.77 (s, 1H), 
7.12 (t, J = 6.8 Hz, 1H), 7.26 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 8 
Hz, 1H), 10.00 (s, 1H). 
Procedure G. 2-{4-[3-(tert-Butyldimethylsilanyloxy)ethyl]piperazine-1-
carbonyl}indole-1-carboxylic acid tert-butyl ester (28). To a stirring solution of amine 
25 (3.55 g, 9.2 mmol) in THF (50 mL), (Boc)2O (2.21 g, 10.1 mmol) and DMAP (1.23 g, 
10.1 mmol) were added at room temperature. The reaction mixture was stirred at the 
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same temperature for 12 h. The crude mixture was evaporated under reduced 
pressure, followed by extraction with CH2Cl2 (3 x 100 mL) in water. The combined 
organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
material was purified by column chromatography over silica gel using ethyl acetate as 
solvent to give compound 28 (4.46 g, ~100%). 1H NMR (CDCl3, 400 MHz): δ 0.05 (s, 
6H), 0.09 (s, 9H), 1.62 (s, 9H), 2.48 (t, J = 4 Hz, 2H), 2.56 (t, J = 6 Hz, 2H), 2.63 (t, J = 
4 Hz, 2H), 3.38 (t, J = 4 Hz, 2H), 3.76 (t, J = 6 Hz, 4H), 6.60 (s, 1H), 7.20-7.28 (m, 1H), 
7.34 (t, J = 7.2 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 8.16 (d, J = 7.6 Hz, 1H). 
2-{4-[3-(tert-Butyldimethylsilanyloxy)propyl]piperazine-1-carbonyl}indole-1-
carboxylic acid tert-butyl ester (29). Amine 26 (3.33 g, 8.3 mmol) was reacted with 
(Boc)2O (2.00 g, 9.1 mmol) and DMAP (1.11 g, 9.1 mmol) in THF (50 mL) using 
procedure G. The crude material was purified by column chromatography over silica gel 
(EtOAc/hexane, 1:1) to give compound 29 (4.04 g, 97%). 1H NMR (CDCl3, 400 MHz): δ 
0.002 (s, 6H), 0.84 (s, 9H), 1.57 (s, 9H), 1.50-1.80 (m, 2H), 2.20-2.70 (m, 6H), 3.30-
3.45 (m, 2H), 3.62 (t, J = 12 Hz, 2H), 3.66-3.80 (m, 2H), 6.55 (s, 1H), 7.18 (t, J = 7.6 Hz, 
1H), 7.29 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H ), 8.12 (d, J = 8.4 Hz, 1H). 
2-{4-[4-(tert-Butyldimethylsilanyloxy)butyl]piperazine-1-carbonyl}-indole-1-
carboxylic acid tert-butyl ester (30). Amine 27 (4.31 g, 10.4 mmol) was reacted with 
(Boc)2O (2.50 g, 11.4 mmol) and DMAP (1.39 g, 11.4 mmol) in THF (50 mL) using 
procedure G. The crude material was purified by column chromatography over silica gel 
(EtOAc/hexane, 1:3) to give compound 30 (4.92 g, 92%). 1H NMR (CDCl3, 400 MHz): δ 
0.001 (s, 6H), 0.84 (s, 9H), 1.25-1.70 (m, 13H), 2.15-2.40 (m, 4H), 2.42-2.55 (m, 2H), 
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3.25-3.45 (m, 2H), 3.47-3.65 (m, 2H), 3.67-3.85 (m, 2H), 6.54 (s, 1H), 7.18 (t, J = 7.2 
Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H).  
2-[4-(2-Hydroxyethyl)piperazine-1-carbonyl]indole-1-carboxylic acid tert-butyl 
ester (31). Compound 28 (4.46 g, 9.2 mmol) was reacted with n-tetrabutylammonium 
fluoride (2.39 g, 9.2 mmol, 1.0 M solution in THF) in THF (30 mL) using procedure E. 
The crude product was purified by silica gel column chromatography (EtOAc/MeOH, 
9:1) to yield compound 31 (3.08 g, 90%). 1H NMR (CDCl3, 400 MHz): δ 1.62 (s, 9H), 
2.46 (t, J = 4.8 Hz, 2H), 2.54-2.68 (m, 4H), 3.41 (t, J = 5.2 Hz, 2H), 3.64 (t, J = 5.2 Hz, 
2H), 3.72-3.78 (m, 2H), 6.60 (s, 1H), 7.21-7.28 (m, 1H), 7.35 (t, J = 8.4 Hz, 1H), 7.54 (d, 
J = 7.6 Hz, 1H), 8.14 (d, J = 7.6 Hz, 1H). 
2-[4-(3-Hydroxypropyl)piperazine-1-carbonyl]indole-1-carboxylic acid tert-butyl 
ester (32). Compound 29 (4.04 g, 8.1 mmol) was reacted with n-tetrabutylammonium 
fluoride (2.11 g, 8.1 mmol, 1.0 M solution in THF) in THF (30 mL) using procedure E. 
The crude product was purified by silica gel column chromatography (EtOAc/MeOH, 
9:1) to yield compound 32 (2.84 g, 91%). 1H NMR (CDCl3, 400 MHz): δ 1.30-1.75 (m, 
11H), 2.33 (m, 2H), 2.47 (t, J = 4.4 Hz, 4H), 3.29 (m, 2H), 3.63 (t, J = 4.8 Hz, 4H), 6.50 
(s, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.24 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 8.05 
(d, J = 8.4 Hz, 1H).  
2-[4-(4-Hydroxybutyl)piperazine-1-carbonyl]indole-1-carboxylic acid tert-butyl 
ester (33). Compound 30 (4.92 g, 9.5 mmol) was reacted with n-tetrabutylammonium 
fluoride (2.50 g, 9.5 mmol, 1.0 M solution in THF) in THF (30 mL) using procedure E. 
The crude product was purified by silica gel column chromatography (EtOAc/MeOH, 
9:1) to yield compound 33 (3.72 g, 97%). 1H NMR (CDCl3, 400 MHz): δ 0.95-1.70 (m, 
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13H), 2.30 (t, J = 6 Hz, 4H), 2.37-2.65 (m, 2H), 3.15-3.36 (m, 2H), 3.37-3.55 (m, 2H), 
3.55-3.82 (m, 2H), 6.48 (s, 1H), 7.12 (t, J = 7.6 Hz, 1H), 7.23 (t, J = 8 Hz, 1H), 7.42 (d, J 
= 8 Hz, 1H), 8.05 (d, J = 8 Hz, 1H). 
2-[4-(2-Oxoethyl)piperazine-1-carbonyl]indole-1-carboxylic acid tert-butyl ester 
(34). Compound 31 (1.0 g, 2.7 mmol) was reacted with oxalyl chloride (0.47 mL, 5.4 
mmol), DMSO (0.76 mL, 10.7 mmol) and Et3N (2.2 mL, 16.1 mmol) in CH2Cl2 (40 mL) 
using procedure A. The crude residue was purified by column chromatography 
(EtOAc/MeOH, 20:1) to afford compound 34 (0.81 g, 81%). 
2-[4-(3-Oxopropyl)piperazine-1-carbonyl]indole-1-carboxylic acid tert-butyl ester 
(35). Compound 32 (0.8 g, 2.1 mmol) was reacted with oxalyl chloride (0.36 mL, 4.1 
mmol), DMSO (0.59 mL, 8.3 mmol) and Et3N (1.73 mL, 12.4 mmol) in CH2Cl2 (40 mL) 
using procedure A. The crude residue was purified by column chromatography 
(EtOAc/MeOH, 20:1) to afford compound 35 (0.62 g, 78%). 
2-[4-(4-Oxobutyl)piperazine-1-carbonyl]indole-1-carboxylic acid tert-butyl ester 
(36). Compound 33 (1.0 g, 2.5 mmol) was reacted with oxalyl chloride (0.43 mL, 5.0 
mmol), DMSO (0.71 mL, 10.0 mmol) and Et3N (2.08 mL, 15.0 mmol) in CH2Cl2 (40 mL) 
using procedure A. The crude residue was purified by column chromatography 
(EtOAc/MeOH, 20:1) to afford compound 36 (0.75 g, 75%). 
2-(4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)propyl 
amino]ethyl}piperazine-1-carbonyl)indole-1-carboxylic acid tert-butyl ester [(±)-
37]. Aldehyde 34 (480 mg, 1.3 mmol) was reacted with (±)-pramipexole (273 mg, 1.3 
mmol) and NaBH(OAc)3 (451 mg, 2.3 mmol) in CH2Cl2 (25 mL) using procedure B. The 
crude material was purified by column chromatography over silica gel (EtOAc/MeOH, 
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9:1) to give compound (±)-37 (0.52 g, 71%). 1H NMR (CDCl3, 400 MHz): δ 0.85 (t, J = 
3.6 Hz, 3H), 1.30-1.65 (m, 2H), 1.60 (s, 9H), 1.95 (d, J = 10.8 Hz, 1H), 2.20-3.10 (m, 
16H), 3.15-3.82 (m, 4H), 4.94 (bs, 2H), 6.58 (s, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.33 (t, J 
= 6.8 Hz, 1H), 7.53 (d, J = 6 Hz, 1H), 8.13 (d, J = 6 Hz, 1H).  
(R)-2-(4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)propyl amino]ethyl} 
piperazine-1-carbonyl)indole-1-carboxylic acid tert-butyl ester [(+)-37]. Aldehyde 
34 (200 mg, 0.54 mmol) was reacted with (+)-pramipexole (114 mg, 0.54 mmol) and 
NaBH(OAc)3 (205 mg, 0.97 mmol) in CH2Cl2 (25 mL) using procedure B. The crude 
material was purified by column chromatography over silica gel (EtOAc/MeOH, 9:1) to 
yield compound (+)-37 (186 mg, 61%). 1H NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 3.6 Hz, 
3H), 1.30-1.65 (m, 2H), 1.61 (s, 9H), 1.95 (d, J = 10.8 Hz, 1H), 2.20-3.10 (m, 16H), 
3.15-3.82 (m, 4H), 4.94 (bs, 2H), 6.58 (s, 1H), 7.25 (d, J = 8.4 Hz, 1H), 7.33 (t, J = 6.8 
Hz, 1H), 7.53 (d, J = 6 Hz, 1H), 8.13 (d, J = 6 Hz, 1H).  
(S)-2-(4-{2-[(2-Amino-4,5,6,7-tetrahydro benzothiazol-6-yl)propyl amino]ethyl} 
piperazine-1-carbonyl)indole-1-carboxylic acid tert-butyl ester [(-)-37]. Aldehyde 34 
(300 mg, 0.81 mmol) was reacted with (-)-pramipexole (170 mg, 0.81 mmol) and 
NaBH(OAc)3 (308 mg, 1.45 mmol) in CH2Cl2 (25 mL) using procedure B. The crude 
material was purified by column chromatography over silica gel (EtOAc/MeOH, 9:1) to 
yield compound (-)-37 (284 mg, 62%). 1H NMR (CDCl3, 400 MHz): δ 0.83 (t, J = 3.6 Hz, 
3H), 1.30-1.65 (m, 2H), 1.61 (s, 9H), 1.95 (d, J = 10.8 Hz, 1H), 2.20-3.10 (m, 16H), 
3.15-3.82 (m, 4H), 4.94 (bs, 2H), 6.58 (s, 1H), 7.25 (d, J = 8.4 Hz, 1H), 7.33 (t, J = 6.8 
Hz, 1H), 7.53 (d, J = 6 Hz, 1H), 8.14 (d, J = 6 Hz, 1H).  
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2-(4-{3-[(2-Amino-4,5,6,7-tetrahydro benzothiazol-6-yl) propyl amino] propyl} 
piperazine-1-carbonyl) indole-1-carboxylic acid tert-butyl ester (38). Aldehyde 35 
(220 mg, 0.57 mmol) was reacted with (±)-pramipexole (121 mg, 0.57 mmol) and 
NaBH(OAc)3 (218 mg, 1.03 mmol) in CH2Cl2 (25 mL) using procedure B. The crude 
material was purified by column chromatography over silica gel (EtOAc/MeOH, 9:1) to 
give compound 38 (215 mg, 65%). 1H NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 7.2 Hz, 
3H), 1.15-1.85 (m, 13H), 1.96 (d, J = 7.2 Hz, 1H), 2.10-2.85 (m, 15H), 2.90-3.15 (m, 
1H), 3.20-3.50 (m, 2H), 3.55-3.95 (m, 2H), 6.58 (s, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.33 (t, 
J = 7.6 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 8.13 (d, J = 8 Hz, 1H). 
2-(4-{4-[(2-Amino-4,5,6,7-tetrahydro benzothiazol-6-yl) propyl amino] 
butyl}piperazine 1-carbonyl) indole-1-carboxylic acid tert-butyl ester (39). 
Aldehyde 36 (233 mg, 0.58 mmol) was reacted with (±)-pramipexole (123 mg, 0.58 
mmol) and NaBH(OAc)3 (222 mg, 1.05 mmol) in CH2Cl2 (25 mL) using procedure B. 
The crude material was purified by column chromatography over silica gel 
(EtOAc/MeOH, 20:1) to yield compound 39 (190 mg, 55%). 1H NMR (CDCl3, 400 MHz): 
δ 0.87 (t, J = 7.2 Hz, 3H), 1.10-1.78 (m, 15H), 1.96 (d, J = 11.2 Hz, 1H), 2.12-2.85 (m, 
15H), 2.90-3.15 (m, 1H), 3.25-3.50 (m, 2H), 3.65-3.92 (m, 2H), 4.78 (s, 2H), 6.60 (s, 
1H), 7.25 (t, J = 7.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 8.15 (d, J 
= 8.4 Hz, 1H). 
(4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl) propyl amino] ethyl} 
piperazin-1-yl)-(1H-indol-2-yl) methanone [(±)-40]. Compound (±)-37 (200 mg, 0.35 
mmol) was reacted with TFA (20 mL) in CH2Cl2 (20 mL) using procedure C. Unreacted 
TFA and solvent were removed under reduced pressure. The TFA salt was converted 
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to the free base by extraction using CH2Cl2 (3 × 100 mL) and a saturated solution of 
NaHCO3. The crude material was purified by column chromatography over silica gel to 
afford compound (±)-40 (228 mg, 80%). 1H NMR (CD3OD, 400 MHz): δ 1.04 (t, J = 7.2 
Hz, 3H), 1.70-1.88 (m, 2H), 2.01-2.18 (m, 1H), 2.32 (d, J = 10.8 Hz, 1H), 2.60-3.60 (m, 
13H), 3.72-4.20 (m, 6H), 6.85 (s, 1H), 7.07 (t, J = 8 Hz, 1H), 7.23 (t, J = 8 Hz, 1H), 7.44 
(d, J = 8 Hz, 1H), 7.62 (d, J = 8 Hz, 1H). 13C (CD3OD, 100 MHz): δ 14.1, 23.0, 26.0, 
26.7, 27.0, 56.6, 57.0, 57.8, 63.1, 109.2, 115.7, 116.3, 124.1, 125.4, 127.9, 131.3, 
132.7, 137.4, 137.5, 167.8, 174.4. The free base was converted to its hydrochloride 
salt. M.p. 270-275 oC. Anal. calculated for C25H40Cl4N6O2S: C, H, N. 
(R)-(4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl) propyl amino] ethyl} 
piperazin-1-yl)-(1H-indol-2-yl) methanone [(+)-40]. Compound (+)-37 (150 mg, 0.26 
mmol) was reacted with TFA (15 mL) in CH2Cl2 (15 mL) using procedure C. Unreacted 
TFA and solvent were removed in vacuo and the salt was washed with diethylether and 
recrystallized from ethanol to afford compound (+)-40 (160 mg, 75%). 1H NMR (CD3OD, 
400 MHz): δ 1.05 (t, J = 7.2 Hz, 3H), 1.70-1.88 (m, 2H), 2.01-2.18 (m, 1H), 2.34 (d, J = 
10.8 Hz, 1H), 2.60-3.60 (m, 13H), 3.72-4.20 (m, 6H), 6.85 (s, 1H), 7.07 (t, J = 8 Hz, 1H), 
7.23 (t, J = 8 Hz, 1H), 7.44 (d, J = 8 Hz, 1H), 7.63 (d, J = 8 Hz, 1H). 13C (CD3OD, 100 
MHz): δ 14.1, 23.0, 26.2, 26.7, 27.0, 56.6, 57.0, 57.8, 63.1, 109.3, 115.7, 116.3, 124.1, 
125.4, 127.9, 131.3, 132.7, 137.4, 137.6, 167.8, 174.4. [α]25D = +25.2° (c = 1.0, 
CH3OH). M.p. 100-110 ºC. Anal. calculated for C31H38.2F9N6O7.6S: C, H, N. 
(S)-(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl) propyl 
amino]ethyl}piperazin-1-yl)-(1H-indol-2-yl)methanone [(-)-40]. Compound (-)-37 (200 
mg, 0.35 mmol) was reacted with TFA (20 mL) in CH2Cl2 (20 mL) using procedure C. 
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Unreacted TFA and solvent were removed in vacuo and the salt was washed with 
diethylether and recrystallized from ethanol to afford compound (-)-40 (237 mg, 83%). 
1H NMR (CD3OD, 400 MHz): δ 1.02 (t, J = 7.2 Hz, 3H), 1.73-1.88 (m, 2H), 2.01-2.18 (m, 
1H), 2.32 (d, J = 10.8 Hz, 1H), 2.60-3.60 (m, 13H), 3.72-4.20 (m, 6H), 6.85 (s, 1H), 7.08 
(t, J = 8 Hz, 1H), 7.23 (t, J = 8 Hz, 1H), 7.44 (d, J = 8 Hz, 1H), 7.62 (d, J = 8 Hz, 1H). 
13C (CD3OD, 100 MHz): δ 14.3, 23.0, 26.2, 26.7, 27.0, 56.6, 57.0, 57.8, 63.1, 109.3, 
115.7, 116.3, 124.1, 125.4, 127.9, 131.3, 132.7, 137.4, 137.5, 167.8, 174.4. [α]25D = 
−31.2° (c = 1.0, CH3OH). M.p. 110-115 ºC. Anal. calculated for C31H40F9N6O8.5S: C, H, 
N. 
(4-{3-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propylamino]propyl}piperazin-
1-yl)-(1H-indol-2-yl)methanone [(±)-41)]. Compound 38 (200 mg, 0.34 mmol) was 
reacted with TFA (20 mL) in CH2Cl2 (20 mL) using procedure C. Unreacted TFA and 
solvent were removed under reduced pressure, followed by washing of the salt with 
diethylether and recrystallization from ethanol to afford compound (±)-41 (266 mg, 
94%). 1H NMR (CD3OD, 400 MHz): δ 1.04 (t, J = 7.6 Hz, 3H), 1.65-1.90 (m, 2H), 1.95-
2.18 (m, 1H), 2.20-2.48 (m, 3H), 2.56-3.70 (m, 12H), 3.78-4.40 (m, 5H), 6.90 (s, 1H), 
7.08 (t, J = 8 Hz, 1H), 7.23 (t, J = 8 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.4 
Hz, 1H). 13C (CD3OD, 100 MHz): δ 10.0, 18.4, 20.1, 21.8, 22.3, 22.7, 51.8, 53.1, 53.6, 
59.2, 104.4, 105.7, 111.8, 120.2, 121.6, 124.2, 127.4, 128.2, 133.7, 136.9, 163.8, 
170.5. M.p. 115-120 ºC. Anal. calculated for C32H42F9N6O8.5S: C, H, N. 
(4-{4-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propylamino]butyl}piperazin-1-
yl)-(1H-indol-2-yl)methanone [(±)-42)]. Compound 39 (175 mg, 0.29 mmol) was 
reacted with TFA (20 mL) in CH2Cl2 (20 mL) using procedure C. Unreacted TFA and 
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solvent were removed under reduced pressure, followed by washing of the salt with 
diethylether and recrystallization from ethanol to afford compound (±)-42 (175 mg, 
71%). 1H NMR (CD3OD, 400 MHz): δ 1.03 (t, J = 7.2 Hz, 3H), 1.50-2.02 (m, 6H), 2.03-
2.20 (m, 1H), 2.35 (d, J = 10.8 Hz, 1H), 2.54-3.70 (m, 18H), 3.74-4.01 (m, 1H), 6.90 (s, 
1H), 7.08 (t, J = 7.6 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.62 (d, J 
= 8.4 Hz, 1H). 13C (CD3OD, 100 MHz): δ 10.0, 18.4, 21.0, 21.7, 22.0, 22.2, 22.7, 51.6, 
56.0, 59.1, 105.7, 105.7, 111.8, 120.3, 121.6, 124.2, 127.4, 128.2, 133.2, 136.9, 163.8, 
170.6. M.p. 100-105 ºC. Anal. calculated for C35H43.6F12N6O9.8S: C, H, N. 
4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)propylamino]ethyl}piperazine-
1-carboxylic acid tert-butyl ester [(±)-43]. Aldehyde 6 (2.4 g, 10.5 mmol) was reacted 
with (±)-pramipexole (2.22 g, 10.5 mmol) and NaBH(OAc)3 (4.01 g, 18.9 mmol) in 
CH2Cl2 (40 mL) using procedure B. The crude material was purified by column 
chromatography over silica gel (EtOAc/MeOH, 20:1) to yield compound (±)-43 (3.34 g, 
75%). 1H NMR (CDCl3, 400 MHz): δ 0.81 (t, J = 7.2 Hz, 3H), 1.10-1.75 (m, 10H), 1.91 
(d, J = 9.6, 1H), 2.10-2.75 (m, 15H), 2.97 (m, 1H), 3.36 (m, 4H), 5.29 (bs, 2H). 
(R)-4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)propylamino]-
ethyl}piperazine-1-carboxylic acid tert-butyl ester [(+)-43]. Compound 6 (1.2 g, 5.25 
mmol) was reacted with (+)-pramipexole (1.11 g, 5.25 mmol) and NaBH(OAc)3 (2.0 g, 
9.46 mmol) in CH2Cl2 (25 mL) using procedure B. The crude material was purified by 
column chromatography over silica gel (EtOAc/MeOH, 20:1) to give compound (+)-43 
(1.63 g, 73%). 1H NMR (CDCl3, 400 MHz): δ 0.83 (t, J = 7.2 Hz, 3H), 1.10-1.75 (m, 
10H), 1.91 (d, J = 9.6 Hz, 1H), 2.10-2.75 (m, 15H), 2.98 (m, 1H), 3.36 (m, 4H), 5.29 (bs, 
2H). 
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(S)-4-{2-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-
yl)propylamino]ethyl}piperazine-1-carboxylic acid tert-butyl ester [(-)-43]. 
Compound 6 (1.2 g, 5.25 mmol) was reacted with (S)-(-)-pramipexole (1.11 g, 5.25 
mmol) and NaBH(OAc)3 (2.0 g, 9.46 mmol) in CH2Cl2 (25 mL) using procedure B. The 
crude material was purified by column chromatography over silica gel (EtOAc/MeOH, 
20:1) to give compound (-)-43 (1.61 g, 71%). 1H NMR (CDCl3, 400 MHz): δ 0.80 (t, J = 
7.2 Hz, 3H), 1.10-1.75 (m, 10H), 1.91 (d, J = 9.6 Hz, 1H), 2.12-2.75 (m, 15H), 2.97 (m, 
1H), 3.36 (m, 4H), 5.29 (bs, 2H). 
N6-(2-Piperazin-1-yl-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine 
[(±)-44]. Compound (±)-43 (3.34 g, 7.88 mmol) was reacted with TFA (20 mL) in CH2Cl2 
(20 mL) using procedure C to give compound (±)-44 (2.30 g, 90%). 1H NMR (CDCl3, 
400 MHz): δ 0.79 (t, J = 7.2 Hz, 3H), 1.25-1.48 (m, 2H), 1.50-1.72 (m, 1H), 1.88 (d, J = 
11.2 Hz, 1H), 2.08-3.07 (m, 19H), 5.40 (bs, 2H).  
(R)-N6-(2-Piperazin-1-yl-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-
diamine [(+)-44]. Compound (+)-43 (1.63 g, 3.84 mmol) was reacted with TFA (15 mL) 
in CH2Cl2 (15 mL) using procedure C to yield compound (+)-44 (1.16 g, 93%). 1H NMR 
(CDCl3, 400 MHz): δ 0.80 (t, J = 7.2 Hz, 3H), 1.25-1.48 (m, 2H), 1.52-1.72 (m, 1H), 1.88 
(d, J = 11.2 Hz, 1H), 2.08-3.07 (m, 19H), 5.40 (bs, 2H). 
(S)-N6-(2-Piperazin-1-yl-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-
diamine [(-)-44]. Compound (-)-43 (1.61 g, 3.80 mmol) was reacted with TFA (15 mL) 
in CH2Cl2 (15 mL) using procedure C to afford compound (-)-44 (1.16 g, 94%). 1H NMR 
(CDCl3, 400 MHz): δ 0.79 (t, J = 7.2 Hz, 3H), 1.25-1.48 (m, 2H), 1.50-1.72 (m, 1H), 1.89 
(d, J = 11.2 Hz, 1H), 2.08-3.07 (m, 19H), 5.41 (bs, 2H). 
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(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propylamino]ethyl}piperazin-1-
yl)-(1H-indol-3-yl)methanone [(±)-45]. Indole-3-carboxylic acid (54 mg, 0.33 mmol) 
was reacted with compound (±)-44 (90 mg, 0.28 mmol) in the presence of EDCI.HCl (80 
mg, 0.42 mmol), TEA (0.12 mL, 0.83 mmol) and HOBt (56 mg, 0.41 mmol) in CH2Cl2 
(10 mL) using procedure F. The crude product was purified by flash column 
chromatography (EtOAc/MeOH, 4:1) to afford compound (±)-45 (83 mg, 64%). 1H NMR 
(CDCl3, 400 MHz): δ 0.87 (t, J = 7.6 Hz, 3H), 1.30-1.52 (m, 2H), 1.55-1.80 (m, 1H), 1.95 
(d, J = 11.6, 1H), 2.20-2.80 (m, 13H), 2.85-3.10 (m, 1H), 3.50-3.82 (m, 4H), 4.86 (bs, 
2H), 7.0-7.38 (m, 4H), 7.60-7.76 (m, 1H), 9.77 (s, 1H). 13C (CDCl3, 100 MHz): δ 12.0, 
14.4, 21.3, 22.5, 25.4, 26.1, 26.8, 48.6, 53.7, 54.2, 58.3, 58.8, 60.6, 111.5, 112.1, 
117.6, 120.4, 121.2, 122.8, 125.6, 127.5, 135.9, 145.3, 165.8, 167.2. The free base 
was converted to its hydrochloride salt. M.p. 170-175 °C. Anal. calculated for 
C25H38.6Cl4N6O1.3S: C, H, N. 
 (R)-(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-
yl)propylamino]ethyl}piperazin-1-yl)-(1H-indol-3-yl)methanone [(+)-45)]. Indole-3-
carboxylic acid (54 mg, 0.33 mmol) was reacted with compound (+)-44 (90 mg, 0.28 
mmol) in the presence of EDCI.HCl (80 mg, 0.42 mmol), TEA (0.12 mL, 0.83 mmol) and 
HOBT (56 mg, 0.41 mmol) in CH2Cl2 (10 mL) using procedure F. The crude material 
was purified by column chromatography over silica gel (EtOAc/MeOH, 4:1) to yield 
compound (+)-45 (87 mg, 67%). 1H NMR (CDCl3, 400 MHz): δ 0.89 (t, J = 7.6 Hz, 3H), 
1.30-1.52 (m, 2H), 1.57-1.80 (m, 1H), 1.95 (d, J = 11.6 Hz, 1H), 2.20-2.80 (m, 13H), 
2.85-3.10 (m, 1H), 3.50-3.82 (m, 4H), 4.87 (bs, 2H), 7.0-7.38 (m, 4H), 7.60-7.76 (m, 
1H), 9.77 (s, 1H). 13C (CDCl3, 100 MHz): δ 12.0, 14.4, 21.4, 22.5, 25.4, 26.1, 26.9, 48.6, 
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53.7, 54.2, 58.3, 58.8, 60.6, 111.6, 112.1, 117.6, 120.4, 121.2, 122.8, 125.6, 127.5, 
135.9, 145.3, 165.9, 167.2. [α]25D = +37.4° (c = 1.0, CH3OH). The free base was 
converted to its hydrochloride salt. M.p. 185-190 oC. Anal. calculated for 
C25H40Cl4N6O2S: C, H, N. 
 (S)-(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-
yl)propylamino]ethyl}piperazin-1-yl)-(1H-indol-3-yl)methanone [(-)-45)]. Indole-3-
carboxylic acid (54 mg, 0.33 mmol) was reacted with compound (-)-44 in the presence 
of EDCI.HCl (80 mg, 0.42 mmol), TEA (0.12 mL, 0.83 mmol) and HOBT (56 mg, 0.41 
mmol) in CH2Cl2 (10 mL) using procedure F. The crude material was purified by column 
chromatography over silica gel (EtOAc/MeOH, 4:1) to give compound (-)-45 (93 mg, 
72%). 1H NMR (CDCl3, 400 MHz): δ 0.85 (t, J = 7.6 Hz, 3H), 1.30-1.52 (m, 2H), 1.55-
1.80 (m, 1H), 1.95 (d, J = 11.6 Hz, 1H), 2.20-2.80 (m, 13H), 2.85-3.10 (m, 1H), 3.50-
3.82 (m, 4H), 4.86 (bs, 2H), 7.0-7.38 (m, 4H), 7.60-7.76 (m, 1H), 9.77 (s, 1H). 13C 
(CDCl3, 100 MHz): δ 12.0, 14.4, 21.3, 22.5, 25.4, 26.1, 26.8, 48.6, 53.8, 54.2, 58.3, 
58.8, 60.6, 111.5, 112.1, 117.7, 120.4, 121.2, 122.8, 125.6, 127.5, 135.9, 145.3, 165.8, 
167.2. [α]25D = −33.6° (c = 1.0, CH3OH). The free base was converted to its 
hydrochloride salt. M.p. 205-210 °C. Anal. calculated for C25H41.5Cl4.5N6O2.5S: C, H, N. 
(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propylamino]ethyl}piperazin-1-
yl)-(1H-indol-5-yl)methanone [(±)-46]. Indole-5-carboxylic acid (60 mg, 0.37 mmol) 
was reacted with compound (±)-44 (100 mg, 0.31 mmol) in the presence of EDCI.HCl 
(89 mg, 0.46 mmol), TEA (0.13 mL, 0.93 mmol) and HOBT (63 mg, 0.46 mmol) in 
CH2Cl2 (15 mL) using procedure F. The crude material was purified by column 
chromatography over silica gel (EtOAc/MeOH, 4:1) to yield compound (±)-46 (102 mg, 
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71%). 1H NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.2 Hz, 1H), 1.40-1.54 (m, 2H), 1.60-
1.81 (m, 1H), 1.97 (d, J = 11.2 Hz, 1H), 2.20-2.72 (m, 14H), 2.90-3.15 (m, 1H), 3.30-
4.02 (m, 4H), 4.89 (bs, 2H), 6.57 (s, 1H), 7.15-7.29 (m, 1H), 7.35 (d, J = 8.4 Hz, 1H), 
7.71 (s, 1H), 8.84 (s, 1H). 13C (CDCl3, 100 MHz): δ 12.0, 22.5, 25.3, 26.0, 26.7, 48.5, 
53.7, 58.3, 58.7, 103.1, 111.4, 117.3, 120.4, 121.4, 125.9, 127.0, 127.5, 136.7, 145.1, 
166.1, 172.2. The free base was converted to its hydrochloride salt. M.p. 185-190 ºC. 
Anal. calculated for C25H41Cl4N6O2.5S: C, H, N. 
(R)-(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-
yl)propylamino]ethyl}piperazin-1-yl)-(1H-indol-5-yl)methanone [(+)-46]. Indole-5-
carboxylic acid (60 mg, 0.37 mmol) was reacted with compound (+)-44 (100 mg, 0.31 
mmol) in the presence of EDCI.HCl (89 mg, 0.46 mmol), TEA (0.13 mL, 0.93 mmol) and 
HOBT (63 mg, 0.46 mmol) in CH2Cl2 (15 mL) using procedure F. The crude material 
was purified by column chromatography over silica gel (EtOAc/MeOH, 4:1) to furnish 
compound (+)-46 (94 mg, 65%). 1H NMR (CDCl3, 400 MHz): δ 0.89 (t, J = 7.2 Hz, 1H), 
1.40-1.54 (m, 2H), 1.60-1.81 (m, 1H), 1.97 (d, J = 11.2 Hz, 1H), 2.20-2.72 (m, 14H), 
2.90-3.15 (m, 1H), 3.30-4.03 (m, 4H), 4.89 (bs, 2H), 6.57 (s, 1H), 7.16-7.29 (m, 1H), 
7.35 (d, J = 8.4 Hz, 1H), 7.71 (s, 1H), 8.84 (s, 1H). 13C (CDCl3, 100 MHz): δ 12.0, 22.5, 
25.3, 26.0, 26.7, 48.5, 53.7, 58.3, 58.7, 103.1, 111.4, 117.3, 120.4, 121.4, 125.9, 127.0, 
127.5, 136.7, 145.1, 166.1, 172.2. [α]25D = +38.6° (c = 1.0, CH3OH). The free base was 
converted to its hydrochloride salt. M.p. 200-205 oC. Anal. calculated for 
C25H40Cl4N6O2S: C, H, N. 
(S)-(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-
yl)propylamino]ethyl}piperazin-1-yl)-(1H-indol-5-yl)methanone [(-)-46]. Indole-5-
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carboxylic acid (60 mg, 0.37 mmol) was reacted with compound (-)-44 (100 mg, 0.31 
mmol) in the presence of EDCI.HCl (89 mg, 0.46 mmol), TEA (0.13 mL, 0.93 mmol) and 
HOBT (63 mg, 0.46 mmol) in CH2Cl2 (15 mL) using procedure F. The crude material 
was purified by column chromatography over silica gel (EtOAc/MeOH, 4:1) to yield 
compound (-)-46 (95 mg, 66%). 1H NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 7.2 Hz, 1H), 
1.40-1.54 (m, 2H), 1.62-1.81 (m, 1H), 1.97 (d, J = 11.2 Hz, 1H), 2.20-2.72 (m, 14H), 
2.90-3.15 (m, 1H), 3.30-4.02 (m, 4H), 4.89 (bs, 2H), 6.58 (s, 1H), 7.15-7.29 (m, 1H), 
7.35 (d, J = 8.4 Hz, 1H), 7.71 (s, 1H), 8.84 (s, 1H). 13C (CDCl3, 100 MHz): δ 12.2, 22.5, 
25.3, 26.1, 26.7, 48.5, 53.7, 58.3, 58.9, 103.1, 111.4, 117.3, 120.4, 121.4, 125.9, 127.1, 
127.5, 136.7, 145.1, 166.1, 172.2. [α]25D = −34.4° (c = 1.0, CH3OH). The free base was 
converted to its hydrochloride salt. M.p. 200-205 oC. Anal. calculated for 
C25H42.1Cl4.5N6O2.8S: C, H, N. 
(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propylamino]ethyl}piperazin-1-
yl)-(5-methoxy-1H-indol-3-yl)methanone (47). 5-methoxy-1H-indole-3-carboxylic acid 
(213 mg, 1.11 mmol) was reacted with compound (±)-44 (300 mg, 0.93 mmol) in the 
presence of EDCI.HCl (267 mg, 1.40 mmol), TEA (0.39 mL, 2.78 mmol) and HOBT 
(188 mg, 1.40 mmol) in CH2Cl2 (25 mL) using procedure F. The crude material was 
purified by column chromatography over silica gel (EtOAc/MeOH, 6:1) to give 
compound 47 (280 mg, 61%). 1H NMR (CDCl3, 400 MHz): δ 0.85 (t, J = 7.2 Hz, 3H), 
1.32-1.48 (m, 2H), 1.56-1.76 (m, 1H), 1.93 (d, J = 10 Hz, 1H), 2.26-2.78 (m, 1H), 2.90-
3.10 (m, 1H), 3.52-3.77 (m, 4H), 3.77 (s, 3H), 5.21 (bs, 2H), 6.77 (d, J = 8.4 Hz, 1H), 
6.90-7.22 (m, 3H), 10.3 (bs, 1H). 
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(4-{2-[(2-Amino-4,5,6,7-tetrahydrobenzothiazol-6-yl)propylamino]ethyl}piperazin-1-
yl)-(5-hydroxy-1H-indol-3-yl)methanone (48). Compound 47 (140 mg, 0.28 mmol) 
was brought to -78 oC in CH2Cl2 (15 mL), followed by dropwise addition of BBr3 (0.13 
mL, 1.41 mmol). The reaction mixture was allowed to stir for 12 h, while gradually 
attaining room temperature. The reaction was quenched by the addition of a saturated 
solution of NaHCO3 and extracted with CH2Cl2 (2 × 100 mL). The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. The crude material was 
purified by flash column chromatography over silica gel (EtOAc/MeOH, 2:1) to give 
compound 48 (80 mg, 59%). 1H NMR (CD3OD, 400 MHz): δ 0.91 (t, J = 7.6 Hz, 3H), 
1.42-1.58 (m, 2H), 1.62-1.80 (m, 1H), 2.00 (d, J = 8.8 Hz, 1H), 2.40-2.85 (m, 15H), 
3.00-3.22 (m, 1H), 3.60-3.88 (m, 4H), 6.74 (dd, J = 8, 1.6 Hz, 1H), 7.04 (d, J = 2.4 Hz, 
1H), 7.24 (s, 1H), 7.53 (s, 1H). The free base was converted to its hydrochloride salt. 
M.p. 210-215 oC. Anal. calculated for C25.8H43.4Cl4N6O3.9S: C, H, N. 
 N6-{2-[4-(1H-Indol-5-ylmethyl)piperazin-1-yl]ethyl}-N6-propyl-4,5,6,7-
tetrahydrobenzothiazole-2,6-diamine (49). Amine (±)-44 (80 mg, 0.25 mmol) was 
reacted with 1H-indole-5-carbaldehyde (36 mg, 0.25 mmol) and NaBH(OAc)3 (94 mg, 
0.45 mmol) in CH2Cl2 (15 mL) using procedure B. The crude residue was purified by 
column chromatography (EtOAc/MeOH, 4:1) to afford compound 49 (71 mg, 63%). 1H 
NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 7.2 Hz, 3H), 1.32-1.54 (m, 2H), 1.60-1.78 (m, 
1H), 1.95 (d, J = 10.4 Hz, 1H), 2.20-2.80 (m, 18H), 2.90-3.10 (m, 1H), 3.63 (s, 2H), 4.87 
(bs, 2H), 6.51 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.19 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 
7.55 (s, 1H), 8.45 (s, 1H). The free base was converted to its hydrochloride salt. M.p. 
230-235 oC. Anal. calculated for C27H49Cl5N6O2S: C, H, N. 
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(S)-N-[6-({2-[4-(1-Acetyl-1H-indole-3-carbonyl)-piperazin-1-yl]-ethyl}-propyl-amino)-
4,5,6,7-tetrahydro-benzothiazol-2-yl]-acetamide [(-)-50]. Compound (-)-45 (30 mg, 
0.06 mmol) in CH2Cl2 (10 mL) was brought to 0 oC and Ac2O (0.03 mL, 0.32 mmol) was 
added dropwise, along with DMAP (0.4 mg, 0.005 mmol). The reaction mixture was 
allowed to stir at room temperature for 12 h. The reaction was quenched by the addition 
of a saturated solution of NaHCO3 and extracted with CH2Cl2. The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. The crude mixture was 
purified over silica gel (MeOH/EtOAc, 1:6) to yield compound (-)-50 (26 mg, 73%). 1H 
NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 7.6 Hz, 3H), 1.40-1.62 (m, 2H), 1.64-1.84 (m, 
1H), 2.20 (s, 3H), 2.36-2.94 (m, 16H), 2.96-3.20 (m, 1H), 3.40-3.86 (m, 3H), 7.18-7.50 
(m, 2H), 7.56 (d, J = 8.4 Hz, 1H), 7.74 (s, 1H), 8.44 (d, J = 8.4 Hz, 1H).   
5-[1,2]Dithiolan-3-yl-pentanoic acid [6-({2-[4-(1H-indole-3-carbonyl)-piperazin-1-yl]-
ethyl}-propyl-amino)-4,5,6,7-tetrahydro-benzothiazol-2-yl]-amide [(-)-51]. DCC (26 
mg, 0.12 mmol) and (R)-lipoic acid (26 mg, 0.12 mmol) in CH2Cl2 (10 mL) were stirred 
at room temperate for 0.5 h, followed by addition of (-)-45 (48 mg, 0.10 mmol) dissolved 
in CH2Cl2. DMAP (3 mg, 0.024 mmol) was finally added and the reaction mixture was 
allowed to stir at room temperature for 12 h. Solvent was removed under reduced 
pressure and crude product was purified over silica gel (MeOH/EtOAc, 1:9) to afford 
compound (-)-51 (44 mg, 66%). 1H NMR (CDCl3, 400 MHz): δ 0.81 (t, J = 7.6 Hz, 3H), 
1.30-1.50 (m, 4H), 1.52-1.74 (m, 5H), 1.98 (d, J = 12 Hz, 1H), 2.25- 2.40 (m, 3H), 2.42-
2.70 (m, 12H), 2.90-3.15 (m, 2H), 3.40-3.75 (m, 8H), 7.06-7.15 (m, 2H), 7.33 (d, J = 7.2 
Hz, 1H), 7.43 (s, 1H), 7.54 (d, J = 7.2 Hz, 1H). 
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5.2  Experimental Procedures   
Reagents and solvents were purchased from commercial suppliers and used as 
received, unless otherwise noted. Dry solvent was obtained following the standard 
procedure. All reactions were performed under N2 atmosphere, unless otherwise 
indicated. Analytical silica gel 60 F254-coated TLC plates were purchased from EMD 
Chemicals, Inc. and were visualized with UV light or by treatment with phosphomolybdic 
acid (PMA), Dragendorff’s reagent or ninhydrin. Whatman Purasil 60A silica gel 230-
400 mesh was used for flash column, chromatographic purifications. Proton nuclear 
magnetic resonance (1H NMR) spectra were measured on Varian 400 MHz FT NMR 
spectrometer, using tetramethylsilane (TMS) as an internal standard. The NMR solvent 
used was CDCl3, unless otherwise indicated. Optical rotations were recorded on Perkin-
Elmer 241 polarimeter. Mass spectra were recorded on Micromass QuattroLC triple 
quadrupole mass spectrometer. Melting points were recorded using MEL-TEMP II 
(Laboratory Devices Inc., USA), capillary melting point apparatus and were uncorrected. 
Elemental analyses were performed by Atlantic Microlab, Inc. and were within ± 0.4% of 
the theoretical value. 
  
Evaluation of binding affinity to and activation of DA D2 and D3 receptors 
Binding potency was measured by the ability of a test compound to inhibit 
[3H]spiroperidol (15.0 Ci/mmole, Perkin-Elmer) binding to rat D2 and D3 receptors 
expressed in HEK-293 cells, in a buffer containing 0.9% NaCl. Functional activity in 
activating human D2 and D3 receptors expressed in CHO cells was measured by the 
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ability of a test compound to stimulate [35S]GTPγS (1250 Ci/mmole, Perkin-Elmer) 
binding, in comparison to stimulation by the full agonist DA.  
Evaluation of antioxidant activity 
DPPH Radical Scavenging Assay. To a 96 well plate, 100 μL of methanolic drug 
solutions ranging from 20 μM to 250 μM were added. Next, 100 μL of 200 μM 
methanolic solution of DPPH (1,1-diphenyl-2-picryl-hydrazyl) was added and the plate 
was shaken vigorously at 30 °C for 20 min. Control wells received 100 μL of methanol 
and 100 μL of 200 μM methanolic DPPH solution. Wells containing only 200 μL of 
methanol served as a background correction. The change in absorbance of all samples 
and standard (ascorbic acid) were measured at 517 nm. Radical scavenging activity 
was expressed as inhibition percentage and was calculated using the following formula: 
% scavenging activity = [(absorbance of control - absorbance of sample)/(absorbance 
of control)] x 100. 
Neuroprotection Studies 
Materials 
1-Methyl-4-phenylpyridinium (MPP+), 6-Hydroxydopamine hydrochloride, Thiazolyl Blue 
Tetrazolium Bromide (MTT), Poly-L-lysine, Dulbecco’s modified Eagle’s Medium, 
Sodium Bicarbonate, Hydrochloric acid, DMSO, methanol, Dulbecco’s phosphate buffer 
saline, Tissue culture grade water were obtained from Sigma-Aldrich. Pennicilin-
Streptomycin and Trypsin were purchased from Invitrogen. Fetal Clone III bovine serum 
(Hyclone, Logan, UT) was purchased from Fisher Scientific. The 96 well plates were 
purchased from Greiner Bio-One. Apo-OneTM Homogeneous Caspase 3/7 reagent was 
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purchased from Promega Inc. (Madison, Wisconsin, USA). RIPA lysis buffer was 
purchased from the Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). BCA protein 
assay reagents and horseradish peroxidase-conjugated rabbit secondary antibody were 
purchased from the Thermo Fisher Scientific Inc. (Rockford, IL, USA). TH primary 
antibody was purchased from the Cell Signaling Technology Inc. (Danvers, MA, USA).  
The anti-GAPDH antibody was purchased from BD Biosciences (San Jose, CA, USA). 
Compounds D-512 ((-)-19) ((6S)-N6-(2-(4-(4-chloro-1H-indol-5-yl)piperazin-1-yl)ethyl)-
N6-propyl-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazole-2,6-diamine) and D-440 ((-)-40)  
((4-(2-(((6S)-2-amino-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazol-6-
yl)(propyl)amino)ethyl)piperazin-1-yl)(1H-indol-2-yl)methanone) were synthesized in our 
lab as described in our recent publication. 
Cell Culture and Treatments 
The hybridoma dopaminergic MN9D cells are derived from the somatic infusion of 
rostral mesencephalic neurons from embryonic C57BL/6J (E14) mice with N18TG2 
mouse cells. They were cultured in T-75 flask (Greiner Bio One, Frickenhausen, 
Germany) coated with 1 mg/ml poly-L-lysine and maintained in DMEM (high glucose 
with phenol red) supplemented with 10% Fecal Clone III serum, penicillin (50 units/ml) 
and streptomycin (50 μg/ml) at 37 °C under 5% CO2 atmosphere. Stock solution of D-
512, D-440 and ropinirole were prepared in DMSO and stored at -20 °C for the period 
of experiments. MN9D cells were pre-treated with various concentrations of D-512, D-
440 or ropinirole and then co-treated with 75 μM 6-OHDA (prepared freshly before 
addition from a stock solution in DMSO stored at -20 °C) or 100 μM MPP+ (prepared 
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freshly before addition from a stock solution in DMSO stored at -20 °C). The control 
cells were treated with the above medium having 0.01% DMSO only. 
Assessment of Cell Viability 
To evaluate the neuroprotection ability of the test compounds in the presence of the 
neurotoxins 6-OHDA and MPP+, the quantitative and colorimetric MTT (3-4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide) tetrazolium salt assay was used to 
assess cell viability. MN9D cells were seeded into poly-L-lysine coated 96-well plates at 
1 × 104 cells/well in 100 μL medium. After the plate was equilibrated for 40 h, old 
medium was taken out from each well and 160 μL of fresh medium (containing 0.01% 
DMSO) was added to control wells, while 160 μL of fresh medium (without DMSO) was 
added to the wells which were to be treated with 6-OHDA or MPP+. A solution of 160 μL 
of D-512, D-440 or ropinirole, in the above medium without DMSO, in 30, 20, 10, 5, 1, 
0.1 μM concentrations were added to wells which would be co-treated with 6-OHDA or 
MPP+. The plate was incubated for 1 h at 37 °C under 5% CO2 atmosphere. At the end 
of incubation, the required amount of 6-OHDA or MPP+ was added to each well (except 
the control wells) to maintain a final concentration of 75 or 100 μM, respectively. The 
plate was then incubated for 24 h at 37 °C under 5% CO2 atmosphere. The next day, 
20 μL of MTT stock solution (prepared in Dulbecco’s phosphate-buffered saline) was 
added to each well to maintain a final concentration of 0.5 mg/ml and the plate was 
incubated for another 3 h at 37 °C under 5% CO2 atmosphere. Next, the plate was 
centrifuged at 1500 rpm for 10 min and the supernatants were removed carefully. The 
formazan crystals were dissolved in 100 μL of a 1:1 mixture of DMSO/Methanol solution 
by shaking gently at 400 rpm for 30 min at ambient temperature on a Thermomix R 
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shaker (Eppendorf, Hamburg, Germany). Finally, absorbance was measured at 570 nM 
and 690 nM using an Epoch microplate reader (BioTek, Winooski, VT, USA).  
Background corrected values (570 nM – 690 nM) values were used to plot the graph.  
Data from at least three experiments were analyzed using GraphPad software (Version 
4, San Diego, USA). 
Fluorometric Caspase-3/7 Assay 
The caspase 3/7 activity was measured by the fluorometric Apo-ONETM Homogeneous 
Caspase 3/7 assay kit following the specification provided by the manufacturer 
(Promega, Madison, WI, USA ) with slight modification. Briefly, 10,000 MN9D cells/well 
were seeded in 90 μL DMEM (with phenol red, containing 10% Fecal Clone III FBS and 
Pen/Strep) in a cell-bind 96 well plate (PLL-coated) and incubated for 48 h at 37 °C 
under 5% CO2.  A solution of 10 μL fresh medium (as mentioned above) without DMSO 
was added to control cells, while 5 μL of fresh medium (as mentioned above) was 
added to the cells which would be treated with 6-OHDA alone. Next, the required 
amount of D-512 was added to the cells which would be co-treated with 6-OHDA, to 
maintain a final concentration of 20 μM and 1 uM, respectively. The plate was shaken 
at 400 rpm for 3 min on an Eppendorf Thermomix shaker to ensure homogeneous 
mixing of the drug. The plate was then incubated for 1 h at 37 °C under 5% CO2 
atmosphere. Next, the required amount of 6-OHDA solution (prepared from a 1 M stock 
solution in DMSO) was added very quickly to the co-treated cells to maintain a final 
concentration of 75 μM. The plate was incubated for 24 h at 37 °C under 5% CO2 
atmosphere. Following incubation, old medium was taken out from each well and 75 μL 
of fresh DMEM medium (high glucose without serum and phenol red) was quickly 
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added to each well. Freshly prepared Caspase-3/7 reagent 75 μL (substrate + lysis 
buffer at 1:100 dilution) was added to each well. The addition of Caspase 3/7 reagent 
was performed in dark. The plate was covered with aluminum foil and shaken at 400 
rpm on an Eppendorf Thermopmix R shaker. Fluorescence reading was taken each 
hour at excitation wavelength of 489 nM and emission wavelength of 535 nM on a 
BioTek Synergy H-1 fluorescence plate reader with sensitivity set to 65. The optimized 
result was obtained at 7 h after the addition of Caspase 3/7 reagent. The value from the 
blank well was substracted from control and treated wells. Data were analyzed using 
GraphPad software (Version 4, San Diego, USA). 
Western Blot Analysis 
A standard protocol was followed to perform Western blotting. In brief, MN9D cells were 
grown in 6-well plates coated with 1mg/ml PLL. After seeding for 24 h, the cells were 
pretreated with 20 μM D-512 followed by co-treatment with 75 μM 6-OHDA for 24 h.  
Cells were then harvested by cell scraping and lysed in RIPA lysis buffer on ice for 30 
min. The supernatant was collected and the protein concentration was determined 
using the BCA protein assay reagents. Samples containing 30 µg of total protein were 
electrophoresed on 12% SDS-polyacrylamide gels and transferred to PVDF membrane.  
The membrane was blocked in 10% nonfat milk in TBST for 1 h followed by probing 
with TH primary antibody overnight at 4 °C.  The membrane was next treated with HRP 
(horseradish peroxidase)-conjugated rabbit secondary antibody for 1 h at ambient 
temperature. The image was visualized using ECL-Plus (PerkinElmer, Waltham, MA, 
USA) and ImageQuant LAS 4000 (GE Healthcare Biosciences, Pittsburgh, PA, USA).  
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GAPDH was used as a house keeping protein to monitor loading control and the 
GAPDH expression levels were determined with an anti-GAPDH antibody. 
 
Anti-Aggregation Studies 
α-syn 
Locomotor Experiment 
Drugs and chemicals: 
The following commercially available drugs were used in the experiment: reserpine 
hydrochloride (Alfa Aesar) and ropinirole (Sigma Aldrich). The trifluoroacetate salt of (-)-
19 and (-)-40 and the hydrochloride salt of (-)-46 and ropinirole were dissolved in water. 
Reserpine was dissolved in 10-25 μL of glacial acetic acid and further diluted with 5.5% 
glucose solution. All compounds for this study were administered subcutaneously (sc), 
in a volume of 0.1-0.3 mL to each rat.  
Animals: 
In rodent studies, animals were male and female, Sprague-Dawley rats from Harlan 
(Indianapolis, IN) weighing 220-225 g, unless otherwise specified. Animals were 
maintained in sawdust-lined cages, in a temperature and humidity controlled 
environment at 22 ± 1°C and 60 ± 5% humidity, respectively. A 12 h light/dark cycle was 
maintained, with lights on from 6:00 AM to 6:00 PM. They were group-housed with 
unrestricted access to food and water. All experiments were performed during the light 
component. All animal use procedures were in compliance with the Wayne State 
University Animal Investigation Committee, consistent with AALAC guidelines.  
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Reversal of Reserpine-Induced Hypolocomotion in Rats: 
Administration of reserpine induces catalepsy in rodents, primarily by blocking the 
vesicular monoamine trasporter (VMAT), which assists in the internalization of 
monoamines into vesicles. VMAT inhibition results in metabolism of unprotected 
monoamines in the cytosol, ultimately causing depletion of monoamines in the 
synapses of the peripheral sympathetic nerve terminals. The ability of compounds (-)-
19, (-)-40 and (-)-46 to reverse reserpine-induced, hypolocomotion was investigated. 
Ropinirole was used as a reference compound in this study. Reserpine (5.0 mg/kg, sc) 
was administered 18 h before the injection of drug or vehicle (sc). The rats were placed 
individually in the chambers 1 h before administration of the test drug, standard drug or 
vehicle for acclimitization. Immediately after administration of drug or vehicle, animals 
were individually placed in versamax animal activity monitor chamber (45 cm × 30 cm × 
20 cm) (AccuScan Instruments, Inc., Columbus, OH) to start measuring locomotor 
activity. Locomotion was monitored for 6 h. Consecutive interruption of two infrared 
beams, situated 24 cm apart and 4 cm above the cage floor, in the monitor chamber 
recorded movement. The data were presented as horizontal activity (HACTV). The 
effect of individual doses of drugs on locomotor activity was compared with respect to 
saline treated controls (mean ± S.E.M.). The data were analyzed by one-way analysis 
of variance (ANOVA) followed by Dunnett’s post hoc test. The effect was considered 
significant if the difference from the control group was observed at p<0.05. 
 
Rotational Experiment 
Drugs and chemicals: 
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The commercially available drug ropinirole (Sigma Aldrich) was used in the experiment. 
The trifluoroacetate salts of compounds D-512 and D-440 and the hydrochloride salt of 
ropinirole were dissolved in water. All compounds for this study were administered 
intraperitoneally (ip) in a volume of 0.5-0.8 mL to each rat. 
  
Animals: 
The lesioned rats (250-260 g) were purchased from Charles River (Wilmington, MA) 
and their unilateral lesion was checked twice by apomorphine challenge following the 
surgery. Animals were maintained in sawdust-lined cages in a temperature and 
humidity controlled environment at 22 ± 1°C and 60 ± 5 % respectively, with a 12-h 
light/dark cycle, with lights on from 6:00 AM to 6:00 PM. They were group housed with 
unrestricted access to food and water. All experiment was performed during the light 
component. All animal use procedures were in compliance with the Wayne State 
University Animal Investigation Committee consistent with AALAC guidelines. 
  
In vivo Rotational experiment with 6-OH-DA lesioned rats 
The first 7 days post-lesion challenge with apomorphine was done with lesioned 
animals to observe a complete rotation session post administration. In the second 
challenge with apomorphine (0.05 mg/kg) 21 days post lesion, contralateral rotations 
were recorded for 30 min; apomorphine produced rotations in all four rats (average 
rotation > 250) indicating successful unilateral lesion. In these rats, lesion was 
performed on the left side of the medial forebrain bundle in the brain and the 
coordinates used from Bregma are: IB +2.5 AP -1.5 ML +/- 1.8 DV -7.5 from the Dura 
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based on Paxinos-Watson Second Addition Atlas. The rotations produced upon agonist 
challenge occurred clockwise. The rats were brought to the test room 1 h before the 
administration of the test drug, standard drug or vehicle for acclimatization. The 
rotations were measured over 7-10 h. For control, vehicle was administered alone.  
Rotations were measured in the Rotomax Rotometry System (AccuScan Instruments, 
Inc. Columbus, Ohio) equipped with Rotomax Analyser, high resolution sensor and 
animal chambers with harnesses.  Data were analyzed with Rotomax Window software 
program. Test drugs D-512 (2.5, 5 and 10 μMol/kg), D-440 (5 and 10 μMol/kg) and 
ropinirole (5 μMol/kg) were each administered ip. The rotations were measured in a 
rotational chamber immediately after administration of drugs. Data was collected at 
discrete 30 min. intervals. Data were analyzed by Graph Pad (Version 4, San Diego) 
program. 
Statistical Analysis 
The data were expressed as mean value ± standard error mean (SEM). For multiple 
groups statistical significance was determined using one way analysis of variance 
(ANOVA) followed Tukey's Multiple Comparison post hoc test. In all cases, P< 0.05 was 
considered statistically significant. 
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Parkinson’s disease (PD) is a progressive, neurodegenerative disorder that 
arises primarily through the loss of dopaminergic neurons in the substantia nigra pars 
compacta, resulting in a diminished level of the neurotransmitter dopamine in the 
nigrostriatal pathway and ensuing loss of motor function. Common symptoms of PD 
include resting tremor, muscular rigidity, bradykinesia (slowness and decreased 
amplitude of movement), along with postural instability and cognitive psychiatric 
complications. PD affects 1% of the population ≥ 65 and is the second most prevalent 
neurodegenerative disorder next to Alzheimer’s disease (AD). Although the etiology of 
PD is not yet clear and may be multifactorial, oxidative stress and mitochondrial 
dysfunction are thought to play a central role in the pathology of the disease. L-dopa, 
the biosynthetic precursor to DA, is the gold-standard treatment option for PD. Although 
initially beneficial in reducing motor symptoms, chronic L-dopa treatment causes 
pharmacoresistant involuntary movements, “on” and “off” phases and may even 
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exacerbate the progression of PD. It has become increasingly evident that for a 
complex disease such as PD, a drug aimed at one target site will only partially address 
the therapeutic need of the disease. Thus, it is hypothesized that multi-functional drugs, 
having multiple pharmacological activities, will be more effective in treating PD. Our 
approach in developing such agents involves alleviating symptoms of the disease, 
along with preventing or halting the neurodegeneration process. To this end, we have 
utilized our hybrid molecular template to design novel, D3-preferring agonists, with a 
range of selectivity for D3 receptor, while also incorporating antioxidant moieties to 
provide antioxidant capacity to the molecule. In this dissertation, we investigate the 
potential of our D3-preferring agonists to both alleviate motor dysfunction and modify 
the progression of PD.   
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